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In recent years, the emphasis in re-
search and clinical practice concern-
ing Alzheimer’s disease (AD) has 
been on early detection of the disease. 
Besides that, ways of measuring the 
progression of AD-related symptoms 
and providing support after the diag-
nosis are also needed. In this study, 
cognition, activities of daily living, 
neuropsychiatric symptoms, and the 
severity of the disease in persons with 
very mild or mild AD at baseline were 
followed up for three years, and the 
usability of the CERAD Neuropsycho-
logical Battery as a follow-up method 
was evaluated. Furthermore, the study 
analysed the effects of early psycho-
social intervention on institutionalisa-
tion and AD-related symptoms.
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ABSTRACT 
 
In developed countries, the change in the age distribution of the population brings on an 
increasing prevalence of disorders that cause memory deficits and dementia. The most 
common of them is Alzheimer’s disease (AD). It is characterised by progressive deficits in 
memory and other cognitive domains, deterioration of daily functions, neuropsychiatric 
symptoms (NPS), and an increasing need of assistance. In order to plan and evaluate the 
necessary treatment and care, one needs knowledge about the progression of AD-related 
symptoms and functional assessment methods. Furthermore, support programmes for 
persons with AD and their caregivers are needed.  
 The aim of this series of studies was to investigate the progression of cognitive deficits 
and other symptoms in persons with very mild or mild AD over a three-year follow-up 
period and to assess the usability of the CERAD Neuropsychological Battery as a follow-up 
method. A further aim was to analyse the effects of early psychosocial intervention on 
institutionalisation and AD-related symptoms.   
 This doctoral dissertation is based on a psychosocial intervention study in Alzheimer’s 
disease, referred to as the ALSOVA Study. It was a prospective, randomised and controlled 
follow-up and intervention study of persons with AD and their caregivers. A total of 241 
participants with recently diagnosed AD were recruited from three hospital districts in 
Finland. Out of those recruited, 236 persons with very mild or mild AD at baseline were 
included and followed up for three years. A total of 129 participated in all four annual 
visits, which included interviews and cognitive assessments by a study nurse and a 
psychologist. Cognition was assessed with the CERAD Neuropsychological Battery and the 
Mini-Mental State Examination (MMSE).  
 The study revealed an association of cognitive performance with the severity of 
dementia and the managing of daily functions. However, cognitive impairment did not 
correlate with NPS. Both cognitive deficits and NPS were associated with the person’s 
ability to manage everyday life activities. Progressive deterioration in cognitive functions 
and in the activities of daily living (ADL) plus increases in NPS were detected during the 
three years. The decline of ADL functions was slower in persons with very mild AD at 
baseline. The CERAD Neuropsychological Battery total score was found to be a suitable 
tool for AD follow-up trials, and a short version of the battery was constructed. The study 
showed no long-term effects of early psychosocial intervention on nursing-home placement 
or AD-related symptoms. 
 In conclusion, the study added to our knowledge of the progression of AD during the 
first few years after diagnosis. It showed up the CERAD Neuropsychological Battery as a 
more sensitive follow-up tool than the MMSE and highlighted the importance of early 
diagnosis and assessment of daily functions and neuropsychiatric symptoms. However, the 
results do not support the recommendation to offer intensive psychosocial intervention to 
all persons with very mild or mild AD.  
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TIIVISTELMÄ 
 
Väestön ikärakenteen muutos kehittyneissä maissa lisää muistivaikeuksien ja 
muistisairauksien määrää. Yleisin muistisairaus on Alzheimerin tauti (AT). Sille on 
tyypillistä etenevät vaikeudet muistamisessa ja muissa tiedonkäsittelytoiminnoissa, 
päivittäisen toimintakyvyn heikentyminen, käytös- ja mielialaoireiden esiintyminen sekä 
lisääntyvä avuntarve.  Tietoa taudinkulusta sekä toimivista arviointimenetelmistä tarvitaan 
hoidon suunnittelua ja arviointia varten. 
 Tämän väitöskirjan tarkoituksena oli selvittää kognitiivisten toimintojen sekä muiden 
oireiden etenemistä hyvin lievää tai lievää Alzheimerin tautia sairastavilla kolmen vuoden 
seurannassa, sekä tutkia CERAD kognitiivisen tehtäväsarjan käytettävyyttä taudin 
etenemisen arviointimenetelmänä. Lisäksi tavoitteena oli selvittää varhaisen 
psykososiaalisen kuntoutuksen vaikuttavuutta laitoshoitoon siirtymiseen ja Alzheimerin 
taudin oireisiin. 
 Väitöskirja pohjautui ALSOVA (Alzheimerin taudin sopeutumisvalmennustutkimus)      
-hankkeeseen, joka on prospektiivinen, satunnaistettu ja kontrolloitu seuranta- ja 
interventiotutkimus. Tutkimukseen osallistui 241 AT:a sairastavaa ja heidän 
omaishoitajaansa kolmen sairaanhoitopiirin alueelta Suomesta. Yhteensä 236 hyvin lievää 
tai lievää AT:a sairastavaa täytti sisäänottokriteerit, ja seuranta kesti kolmen vuoden ajan. 
Yhteensä 129 tutkittavaa osallistui kaikille neljälle tutkimuskäynnille. Vuosittaiset käynnit 
sisälsivät tutkimushoitajan ja psykologin tekemiä haastatteluja ja kognitiivisen arvioinnin. 
Kognitiivisia tomintoja arvioitiin CERAD tehtäväsarjalla sekä MMSE-testillä. 
 Väitöskirjaan sisältyvien tutkimusten mukaan kognitiivinen suoriutuminen oli 
yhteydessä taudin vaikeusasteeseen ja päivittäiseen toimintakykyyn. Sen sijaan yhteyttä 
kognition ja neuropsykiatristen oireiden välillä ei todettu. Sekä kognitio että 
neuropsykiatriset oireet olivat yhteydessä AT:a sairastavan kykyyn suoriutua päivittäisistä 
toimista. Kolmen vuoden aikana kognitiiviset toiminnot ja päivittäinen toimintakyky 
heikkenivät etenevästi ja neuropsykiatriset oireet lisääntyivät. Päivittäisen toimintakyvyn 
lasku oli hitaampaa henkilöillä, joilla oli hyvin lievä AT tutkimuksen alussa. CERAD 
kognitiivisen tehtäväsarjan kokonaispistemäärä osoittautui toimivaksi mittariksi 
seurantatutkimuskäytössä, ja lisäksi kehitettiin tehtäväsarjan lyhyt versio. Varhaisella 
psykososiaalisella kuntoutuksella ei todettu olevan pitkäkestoisia vaikutuksia laitoshoitoon 
siirtymiseen tai AT:n oireisiin.  
 Tutkimus tuotti lisää tietoa AT:n etenemisestä ensimmäisinä vuosina taudin toteamisen 
jälkeen. CERAD tehtäväsarjaa voidaan suositella MMSE-testiä herkempänä menetelmänä 
taudin seurannassa. Tulokset korostavat varhaisen taudin toteamisen sekä päivittäisen 
toimintakyvyn ja neuropsykiatristen oireiden arvioimisen merkitystä. Sen sijaan tulokset 
eivät tue psykososiaalisen kuntoutuksen tarjoamista kaikille lievää AT:a sairastaville.  
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 1 Introduction 
Alzheimer’s disease (AD) is a progressive neurodegenerative disease and the most common 
cause of dementia. The prevalence of disorders that cause memory deficits and dementia 
increases as the population ages. The present number of persons with dementia in Finland 
has been estimated to be approximately 120 000 (Memory disorders: Current Care 
Guidelines, 2010), and by 2050 the number has been estimated to double (Alzheimer’s 
Association, 2014). AD is characterised by progressive memory deficits, problems in other 
cognitive domains, decline in daily functions, and behavioural and psychological problems 
(Cummings, 2007). Researchers have identified the brain pathology and many protective 
and risk factors involved in AD (e.g., Seppälä et al., 2013; di Marco et al., 2014), but the 
ultimate cause of AD onset is still unknown, and no inhibitory or interceptive medication is 
available. 
 Recent research and clinical practice have focused on early detection of AD, and less 
attention has been paid to following up the progression of the disease. The course of the 
disease has been documented, and predictors of rapid progression of AD have been sought. 
Unfortunately, the measures used have been variable and the follow-up periods often 
limited. Oftentimes, only the MMSE test (Folstein et al., 1975) has been used as a measure of 
global cognition and the severity of the disease; this practice has also been criticised (e.g., 
Atchinson et al., 2004; Clark et al., 1999). At the same time, scientific knowledge and 
diagnostic criteria have advanced substantially in recent decades. Persons can now be 
diagnosed at an earlier stage of the disease (Dubois et al., 2010; Jack et al., 2011; American 
Psychiatric Association, 2013), and AD-targeted medication is available to slow down the 
progression of the disease (Memory disorders: Current Care Guidelines, 2010). There is 
thus a clear need of further studies to track the course of the disease in medicated persons 
with very mild or mild AD.  
 The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) was founded 
as early as the 1980s to develop standardised measures for the assessment of AD. The 
CERAD Neuropsychological Battery (CERAD-NB), developed to measure early cognitive 
impairments in AD (Welsh et al., 1994), was translated into Finnish in the 1990s (Hänninen 
et al., 1999). Nowadays the CERAD-NB is used as a screening tool for AD-related cognitive 
deficits (Sotaniemi et al., 2012). The CERAD-NB total score (Chandler et al., 2005), 
developed later, has also proved to be a reliable measure to distinguish early AD from 
normal aging (Paajanen et al., 2013). But as to the use of the CERAD-NB as a follow-up tool 
to measure the progression of AD-related symptoms, much less is known. Because the 
CERAD-NB is widely used at the stage of diagnosis, it would make sense to extend its use 
to follow-up as well. In research settings in particular, the CERAD-NB total score might be 
a more accurate measure of global cognition than the MMSE, besides being easier to use in 
analyses than the single cognitive tests that measure different cognitive domains.   
 Due to the increasing costs of dementia care and the sharpened awareness of the effects 
of the disease on the lives of people with AD and their caregivers, different kinds of 
interventions have been developed to ease AD-related symptoms, to reduce caregiver 
burden, and to delay nursing-home placement (Pinqart & Sörensen, 2006; Olazar et al., 
2010; van Mierlo et al., 2010; Vernooij-Dassen et al., 2011). However, the results have been 
contradictory. Previous literature indicates that different clinical characteristics of the 
participants affect the efficacy of the interventions and that the outcomes attained may also 
vary according to the particular interventions used. Only multicomponent interventions 
have succeeded in delaying nursing-home placement, but some recent studies have failed 
to show any long-term effects of psychosocial intervention on institutionalisation.  
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 In this study, persons with recently diagnosed very mild or mild AD at baseline and 
their caregivers were followed up for three years. On annual study visits, a wide range of 
evaluations was carried out. The participants were randomised into control groups and 
intervention groups, and the members of both groups participated in the study visits and 
visits to their regular health-care system. The psychosocial intervention courses were 
arranged during the first two years of the study. The aim of the study was to evaluate the 
course of the disease during the three years after diagnosis, focusing on cognition, daily 
functions, and neuropsychiatric symptoms. Furthermore, the effects of early psychosocial 
interventions on AD-related symptoms and nursing-home placement were evaluated and 
the usability of the CERAD-NB as a follow-up tool was assessed. The assessment focused 
on the use of the CERAD-NB total score and the subtests of the CERAD-NB over the three-
year follow-up period. To advance the follow-up of the progression of AD-related 
symptoms, a short version of the CERAD-NB was constructed.  
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2 Review of the Literature 
2.1 ALZHEIMER’S DISEASE  
In 1906, Dr. Alois Alzheimer described the case of Auguste D, a patient who suffered from 
a form of dementia; later on, the condition became known as Alzheimer’s disease (AD) 
(Maurer et al., 1997). Nowadays AD is known to be a progressive neurodegenerative 
disease. The term dementia is used to describe a condition in which the deterioration of 
cognition affects the person’s ability to perform everyday activities (Alzheimer Association, 
2014; American Psychiatric Association, 1994; 2013), and AD is the most common cause of 
it, accounting for 50 - 80 % of the cases (Plassman et al., 2007; Alzheimer’s Association, 
2014). AD is a condition typically characterised by progressive deterioration of memory, 
accompanied by other cognitive, behavioural, and psychological changes, which eventually 
affect the person’s everyday life and social functions and causes an increasing need for 
assistance (Small et al., 2009; World Health Organization, 2012; Alzheimer’s Association, 
2014). During the last few decades, scientific knowledge and clinical practice pertaining to 
AD have advanced substantially and continue to do so. In describing the large scientific 
field of AD-related symptoms and AD pathology, it is therefore more appropriate to refer 
to handbooks, reviews, consensus and position papers, and reports rather than single 
scholarly articles. 
The pathological process of AD begins years or decades before any clinical symptoms 
emerge. The hallmarks of AD pathology are progressive accumulation of the protein beta-
amyloid outside neurons, seen as senile plaques, accompanied by abnormalities in the 
synaptic function and eventually leading to the death of neurons, which is seen as an 
abnormal form of the protein tau (neurofibrillary tangles) accumulation inside neurons 
(Small et al., 2009; Alzheimer’s Association, 2014; Seppälä et al., 2013). According to present 
knowledge, AD develops as a result of diverse risk and protective factors. The most 
important risk factor for dementia is age. Approximately 3.0 % of women and 2.3 % of men 
aged 65 - 69, and 24.7 % and 17.4 %, respectively, aged 85 - 89 have dementia (Prince et al., 
2013). The prevalence doubles with every five-year increment in age after 65 (World Health 
Organization, 2012). Other known risk factors include a family history of AD (Donix et al., 
2012), and the apolipoprotein E ε4 allele (Farrer, 1997; Weiner et al., 2013). Disease-
modifying factors may increase or decrease the risk of AD. Cardiac and cardiovascular 
disease risk factors such as high blood pressure, obesity (Kivipelto et al., 2005; Meng et al., 
2014), diabetes (Meng et al., 2014), smoking (Rusanen et al., 2010; di Marco et al., 2014), high 
cholesterol (Solomon et al., 2009; Meng et al., 2014) at mid-life, and traumatic brain injury 
(Shively et al., 2012) have also been found to increase the risk of AD. Some studies have 
shown an association between a healthy diet and decreased risk of AD (Eskelinen et al., 
2011). A recent review, however, reported conflicting results concerning the protective role 
of healthy dietary habits (di Marco et al., 2014). Social and cognitive activity has been found 
to protect against dementia (di Marco et al., 2014), and there have been promising results 
concerning the effects of physical exercise on cognitive functions in old age (Kirk-Sanchez 
& McGough, 2014).  
The change in the age distribution of the population and the consequent increase of 
memory disorders pose a challenge to the society and its health-care system. In the United 
States, approximately 11 % of people who are 65 or older, and about one third of people 
aged 85 or older, have AD (Alzheimer’s Association, 2014). Worldwide, 35.6 million people 
were estimated to have dementia in 2010, and there are 7.7 million new dementia cases each 
year (World Health Organization, 2012). In Finland, approximately 35 000 people have been 
estimated to have mild dementia and 85 000 people to have at least moderate dementia, 
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and approximately 13 000 people are found to contract a memory disorder every year 
(Memory disorders: Current Care Guidelines, 2010The numbers are expected to almost 
double every 20 years (Prince et al., 2013). However, some recent studies (Schrijvers et al., 
2012) indicate that the incidence of dementia may be descending. Yet Solomon et al. (2014) 
point out that it is difficult to know whether the real incidence of dementia-related diseases 
has changed during the last few decades, for the diagnosing of memory diseases has been 
influenced by factors such as revised diagnostic criteria, increasing awareness, and several 
new drugs developed after the year 2000. The average life expectancy of people with AD is 
four to ten years after the diagnosis (Ganguli, 2005; Waring, 2005; Helzner, 2008; Xie, 2008; 
American Psychiatric Association, 2013), partly because persons with AD are at an 
advanced age. Some of them live even 20 years with the disease (American Psychiatric 
Association, 2013). AD affects not only the wellbeing of the persons with the disease 
(Karttunen et al., 2011) but the whole family and the family caregivers as well (World 
Health Organization, 2012; Välimäki et al., 2014). In Finland, the direct costs of AD therapy 
and care were estimated to be about one billion dollars in 2009, and the total costs of AD 
amounted to about 1.3 – 1.7 billion dollars when the costs of family caregiving were taken 
into account. The annual costs of care per each person with AD was approximately 17 000 – 
25 000 dollars (Wimo et al., 2010). 
 
2.2 THE CONTINUUM OF ALZHEIMER’S DISEASE 
Cognitive functions include different skills, such as memory, language, psychomotor speed, 
visuospatial functions, and executive functions. These skills are needed in processing 
information and thus in everyday life. Memory can be divided into different components 
according to time (short-term and long-term memory) or content (Squire, 2004; Salmon & 
Bondi, 2009). Long-term memory can be divided into declarative and non-declarative, 
where the former includes conscious remembering and the latter, unconscious effects of 
previous experiences (e.g., skills and habituation). Declarative memory can be further 
divided into episodic memory (remembering events and experiences) and semantic 
memory (knowledge) (Squire, 2004). The most typical cognitive domains affected by 
normal aging are the learning phase and the recall phase of memory and the speed of 
performance, but no remarkable forgetting from long-term memory should normally 
happen (Salmon & Bondi, 2009).  
2.2.1 Mild Cognitive Impairment (MCI), prodromal Alzheimer’s disease, and dementia 
AD pathology begins to develop in the brain many years before any symptoms arise. The 
continuum of AD proceeds from the pre-symptomatic phase to the phase where mild 
memory problems or problems in other cognitive domains are manifested, and finally to 
the phase where the symptoms interfere with the person’s ability to work or to carry out 
daily activities or affect the person’s social skills (Albert et al., 2011; Jack et al., 2011; 
Sperling et al., 2011; Seppälä et al., 2013).  
 There is a transitional phase between normal ageing and the phase where a disease that 
causes dementia can be diagnosed. The term mild cognitive impairment (MCI) has been 
used to describe this grey area between intact cognitive functioning and clinical dementia 
(Petersen, 2014). In MCI, at least one cognitive domain deteriorates more than would be 
expected for the person’s age and educational background. Even so, persons with MCI 
carry out their daily tasks independently or with minimal assistance. Cognitive deficits may 
cause mild problems in complex tasks but do not result in any significant impairment of 
social or occupational functioning (Albert et al., 2011). This heterogeneous condition may 
be associated with various underlying etiologies (Dubois et al., 2010).  
 MCI constitutes a risk of AD and other dementias. Specific diagnostic criteria for MCI 
due to AD were proposed in 2011 (Albert et al.). Dubois et al. (2010) point out that 
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traditionally the term MCI has included persons who could be diagnosed to have 
symptomatic prodromal AD according to the new criteria. They suggest that MCI or 
amnestic MCI should be kept as a classification that includes individuals who do not meet 
these criteria. They propose the term prodromal AD or predementia stage of AD to be used 
to characterise the early symptomatic phase in which clinical symptoms, including episodic 
memory loss, are present but not sufficiently severe to affect the person’s daily life and thus 
do not warrant a diagnosis of dementia and in which the biomarker evidence is supportive. 
In their Diagnostic and statistical manual of mental disoders, 5th edition (DSM-5) (2013), the 
American Psychiatric Association defined the concept of mild neurocognitive disorder due 
to AD, which is equivalent to the concept of MCI due to AD. However, not all individuals 
with MCI become demented. The term dementia is used to describe a condition where the 
deterioration of memory or another cognitive domain affects the person’s ability to perform 
everyday activities and causes an increased need of assistance (Alzheimer Association, 
2014; American Psychiatric Association, 1994; 2013). 
2.2.2 Diagnostic criteria of Alzheimer’s disease 
The criteria that have been most commonly used for diagnosing AD include the DSM-IV 
(American Psychiatric Association, 1994) and the criteria of the National Institute of 
Neurological and Communicative Disorders and Stroke and the Alzheimers Disease and 
Related Disorders Association (NINCDS-ADRDA; McKhann et al., 1984). These criteria 
have been recently updated (DSM-5; American Psychiatric Association, 2013; McKhann et 
al, 2011). 
Dubois et al. (2010) and Jack et al. (2011) have reviewed the history and development of 
the diagnostic criteria for AD. AD has been conceptualised as a clinico-pathological 
condition that requires a clinical phenotype typically centred on the presence of progressive 
dementia, which includes episodic memory impairment, deterioration of other cognitive 
domains, and specific neuropathological changes (Cummings et al 2007; Dubois et al. 2010; 
Jack et al., 2011). As neuropathological investigations cannot be performed on live patients, 
AD has been a predominantly clinical entity diagnosed as probable AD (McKhann 1984; 
Dubois et al., 2010). It has been assumed that in most cases the subjects who met the clinical 
criteria had AD pathology as the underlying etiology (Jack et al., 2011). A diagnosis can be 
made only at the dementia stage by excluding other possible causes (Dubois et al., 2010).  
However, scientific knowledge about AD pathology has somewhat increased over the 
last few decades. Laboratory cerebrospinal fluid (CSF) and neuroimaging biomarkers 
correlate with the neuropathological lesions of AD (Dubois et al., 2010). In 2007, the 
International Work Group proposed a new diagnostic framework for research settings with 
the intention to move beyond the NINCS-ADRDA criteria, and this framework has been 
recently specified (Dubois et al., 2007; Dubois et al., 2010). The diagnosis should be made 
with both clinical and in-vivo biological evidence of AD pathology present (Dubois et al., 
2010). In 2009 the National Institute of Aging (NIA) and the Alzheimer’s Association’s work 
group also started to revise the diagnostic criteria so as to incorporate the new scientific 
advances. They formulated new diagnostic criteria separately for the dementia phase, the 
symptomatic non-dementia phase (MCI due to AD), and the asymptomatic preclinical 
phase of AD (Jack et al., 2011). The main two differences from the NINCS-ARDRA criteria 
(1984) concern the incorporation of biomarkers of the underlying disease state and the 
formalisation of the different stages. However, as Jack et al. (2011) emphasise, a great deal 
of additional work is needed to validate the application of biomarkers for diagnostic 
purposes. For clinical practice, they recommend clinical criteria for diagnosing AD 
dementia and MCI due to AD, but preclinical criteria they recommend for research 
purposes only. The clinical phase of AD-related dementia can be considered to have been 
reached when there are cognitive symptoms severe enough to interfere with the person’s 
social functioning and activities of daily life and there are changes in episodic memory and 
at least in one other cognitive domain. Typical AD is characterised by progressive 
6 
 
impairment of episodic memory, followed by other cognitive impairments and 
neuropsychiatric changes and supported by in-vivo biomarkers (Dubois et al., 2010). One 
can also distinguish atypical AD, which has a less common but well characterised clinical 
phenotype occurring with AD pathology (Dubois et al., 2010). 
In the diagnosis of dementia due to Alzheimer’s disease according to the DSM-IV 
(American Psychiatric Association, 1994), the person is presumed to have a progressive 
deficit in memory and at least in one other cognitive domain with a gradual onset that 
causes significant impairment in social or occupational functioning and cannot be 
accounted for by reference to other reasons. The revised diagnostic criteria presented in 
DSM-5 are still based on cognitive, functional, and clinical features of AD, and the 
significance of standardised neuropsychological testing is emphasised. In addition, it is 
suggested that diagnostic markers (Positron Emission Tomography, PET; Magnetic 
Resonance Imaging, MRI; Cerebrospinal fluid, CSF) may have diagnostic value. A major 
cognitive disorder is distinguished from a mild one on the basis of their effects on everyday 
activities, and physicians are required to specify whether the condition is due to AD or 
other conditions.  
 
2.2.3 Cognition and the phases of dementia in relation to brain pathology 
According to Braak’s hypothesis, progressive neurofibrillary changes begin from the 
entorhinal cortex and the hippocampus-related medial temporal structures and 
subsequently spread to the neocortical association areas (Braak et al., 1991; Dubois et al., 
2010). This pathway of regional neuropathology correlates with the typical pattern of 
cognitive changes in AD (Dubois et al., 2010). The clinical dementia rating reflects the 
gradual development of the clinical severity of the disease, corresponding to stage IV and 
higher in Braak’s model (Jack et al., 2011). In regard to severity, the phases of AD have been 
divided into the mild, the moderate, and the severe one (Hughes et al., 1982; Morris et al., 
1993). 
 Patophysiological biomarkers (SCF) correspond to some extent to the etiological 
degenerative processes that characterise AD pathology, the amyloidosis path to neuronal 
plaques, and the extent of the regional distribution of neurofibrillary tangles (the tauopathy 
path) mainly in early stages of the disease. Topographical biomarkers (MRI, PET scans) are 
used to assess the brain changes that typically correlate with the regional distribution of AD 
pathology, including medial temporal lobe atrophy (MRI) and reduced glucose metabolism 
in tempo-parietal regions (PET) (Dubois et al., 2010; Jack et al., 2011; Seppälä et al., 2013). 
The pathophysiological changes precede the topographical changes associated with 
neurodegeneration, starting during the long preclinical phase, whereas the development of 
neurofibrillary pathology accelerates slightly before the onset of the symptomatic phase of 
AD. The structural brain changes map onto the Braak stages of neurofibrillary tangle 
deposition, and neurodegeneration, particularly synapse loss, is most closely coupled with 
cognition (Dubois et al., 2010; Jack et al., 2009; 2011). The progression of clinical symptoms 
is a close parallel of the progressive worsening of neurodegenerative biomarkers (Jack et al., 
2011). In the past decade, however, a better understanding of the distinctions and overlaps 
between non-AD and AD has been reached (Jack et al., 2011). There is also a clinical variant 
of AD that does not follow the typical AD phenotype (Dubois et al., 2010).  
 Table 1 presents typical cognitive symptoms of very mild, mild, moderate, and severe 
AD and their consequences for the person’s everyday life. In the very mild phase there are 
notable problems with episodic memory and learning, mild problems in executive 
functions or other cognitive domains may show up, and the person has problems in 
complex everyday tasks, such as financial issues. Persons in the very mild phase typically 
ask the same questions over and over or recall events partially. The mild phase of the 
disease is characterised by moderate problems in memory and in time relationships. The 
person has difficulty in learning new things and forgets them quickly. Problems in 
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executive functions and language skills, e.g., naming, start to emerge. Perception deficits 
may also occur. These changes affect the person’s instrumental activities of daily living 
(IADL), such as shopping, cooking, driving, or finding a route from one place to another. 
Apathy, depression, irritability, and paranoid beliefs are typical neuropsychiatric 
symptoms, and the person’s awareness of his or her deficits may be lacking. In the 
moderate phase, the memory loss and the orientation problems are severe. The person 
forgets new things quickly and finds it difficult to recall even old things. There are also 
remarkable problems in other cognitive domains, such as speaking and understanding, the 
visuospatial domains, and attention. The person needs assistance in the basic activities of 
daily living, such as dressing and personal hygiene. In the severe phase of the disease, the 
person needs constant assistance (Hughes et al., 1982; Kuikka et al., 2002; Pirttilä et al., 
2010). Although AD causes significant functional deficits, social cognition and procedural 
memory (e.g., dancing) may be preserved relatively well for extended periods (American 
Psychiatric Association, 2013). 
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2.2.4 Neuropsychiatric symptoms 
Terms neuropsychiatric symptoms (NPS), non-cognitive symptoms, and behavioural and 
psychological symptoms have been used to describe a wide range of non-cognitive 
manifestations of AD. An international group of experts (The Neuropsychiatric Syndromes 
of AD Professional Interest Area (NPS-PIA) of the International Society to Advance 
Alzheimer’s Research and Treatment (ISTAART)), have divided the NPS in AD into five 
syndromic areas: depression, apathy, sleep, agitation, and psychosis (Geda et al., 2013). 
Earlier, NPS were thought to emerge primarily in more severe stages of AD, but currently 
they are known to appear frequently in very early and even prodromal phases of the 
disease (Lyketsos et al., 2011; Dillon et al., 2013). From the perspective of the caregiver, 
friends, family, clinicians, and persons with AD, NPS are often the most difficult problems 
to deal with (Dillon et al., 2013; Kales et al., 2013), and they often get worse as AD 
progresses. The manifestation of NPS may fluctuate during the course of the disease (Dillon 
et al., 2013), but eventually they affect almost all patients with serious consequences (Geda 
et al., 2013) and commonly lead to early nursing home placement, hospitalisation, and 
caregiver stress (Kales et al., 2013).  
 Imaging has implicated some underlying neurobiological causes for the occurrence of 
NPS in AD, but the relationship between primary AD pathology and NPS remains to be 
elucidated (Geda et al., 2013). Dillon et al. (2013) sum up that NPS probably arise through 
interaction among psychological, social, and biological causes, including neurochemical, 
neuropathological, and genetic factors. Geda et al. (2013) have proposed four possible 
mechanisms for the relationship between AD and NPS. The etiological pathway model 
proposes that NPS reflect an underlying pathology, which is causally linked to the 
development of AD pathology. Another explanation proposes that there are shared risk or 
confounding factors that lead to both AD and NPS. Neuropsychiatric symptoms may also 
be a direct cause of AD. A person may have depression or anxiety, for example, as a 
psychological reaction to cognitive problems. Furthermore, AD may affect key brain areas 
underlying one’s behaviour and emotions. The fourth mechanism proposed assumes that it 
is interaction between NPS and biological factors that leads to AD (Geda et al., 2013).  
2.2.5 Clinical features of Alzheimer’s disease 
Knowledge about the natural course of the disease is needed for planning and evaluating 
suitable care and treatment and providing persons with AD and their families with 
information about the first years in the course of the disease. Table 2 summarises some 
relevant follow-up studies of AD conducted over the past ten years. Interpreting the results 
is rather challenging, however, because of variation in the use of terms and measures and 
differences in the populations studied and the follow-up periods employed. Generally, 
cognition and daily functioning deteriorated and NPS tended to increase during the follow-
up period. Cognitive deterioration seemed to be slower during the mild phase of the 
disease (Feldman et al., 2005), and in some studies the rate of decline was non-linear 
(Bozoki et al., 2009; Vellas et al., 2012). Also, the rate of cognitive decline varied among 
individuals (Bozoki et al., 2009; Cotes et al., 2008; Gillette-Guyonnet et al., 2011), and some 
persons with AD were found to be stable even years after the onset of dementia (Cortes et 
al., 2008; Tschanz et al., 2011). Recently, it has been proposed that deterioration may occur 
at a slower rate than previously thought (Gillette-Guyonnet et al., 2011; Vellas et al., 2012); 
such observations may be due to improved diagnostic procedures and treatments.  
 Measures of daily functioning seem to be more sensitive than cognitive measures to 
discern changes in the characteristics of persons with AD. According to a French follow-up 
study (Cortes et al., 2005; Cortes et al., 2006; Cortes et al., 2008; Nourhashemi et al., 2008; 
Nourhashemi et al., 2009; Gillette-Guyonnet et al., 2011), activities of daily living 
deteriorated faster in the oldest age group (<85 years). Furthermore, ADL functions 
deteriorated more slowly in persons at the very mild phase of the disease (CDR=0.5) than 
11 
 
persons with more advanced dementia. No corresponding group differences were observed 
in regard to the rate of cognitive decline. 
 Apathy and depression are the most prevalent neuropsychiatric symptoms in AD (Serra 
et al., 2010; Karttunen et al., 2011; Dillon et al., 2013). Other common symptoms include 
psychotic symptoms (hallucinations, delusions, paranoia), agitation and irritability (Dillon 
et al., 2013). In particular, apathy (Dillon et al., 2013), delusions and irritability (Serra et al., 
2010) increase with the progression of the illness. Features typical for AD also include 
euphoria, sleep and appetite disturbances, and motor restlessness (Cummings et al., 2007; 
Dillon et al., 2013). Most studies indicate that neuropsychiatric symptoms (NPS) and 
cognition are not substantially related (Dillon et al., 2013) but are rather individual 
manifestations of AD; however, opposite results have also been reported (Serra et al., 2010). 
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2.2.6 Predicting the progression of symptoms in Alzheimer’s disease 
Many studies have have sought to find out how the personal characteristics and the 
cognitive profile of the person with AD at the time of the diagnosis could be used to predict 
the course of the disease. This information would be helpful for planning the treatment, the 
care, and the follow-up needed. Traditionally, a rapid cognitive decline is often defined in 
terms of a reduction in the score of the Mini-Mental State Examination (MMSE, Folstein et 
al., 1975) (Marra et al., 2000; Atchison et al., 2004; Buccione et al., 2007; Musicco et al., 2009, 
2010; Palmer et al., 2011; Sona et al., 2013). But this method has also been criticised for being 
insensitive to the progression of AD (Atchinson et al., 2004; Clark et al., 1999), and its 
limitations, e.g., with aphasia patients, have been acknowledged (Schmidt et al., 2011). 
Table 3 presents studies in which a rapid progression of AD symptoms was predicted with 
baseline assessments.  
 Neuropsychological tests have been used to predict the progression of AD-related 
symptoms. However, many of the studies were conducted in the 1990s, and the variability 
in their use of measures complicates their interpretation. Previous studies have found the 
predictors of rapid symptom progression to include impairment in executive function and 
attention (Musicco et al., 2010; Marra et al., 2000), in verbal memory and language skills 
(Marra et al., 2000; Cosentino et al., 2006), in visuospatial and visuoconstructional skills 
(Sarazin et al., 2005; Atchinson et al., 2007), in the processing speed (Atchinson et al., 2007), 
and in short-term memory (Sarazin et al., 2005). Accordingly, other cognitive skills than 
performance in delayed-memory tasks may be better predictors of the progression of AD-
related symptoms. The global severity of cognitive impairment at the time of the diagnosis 
(Atchinson et al., 2004; Sarazin et al., 2005; Buccione et al., 2007; Ousset et al., 2008; Lopez et 
al., 2010) has also been found to predict a rapid progression of AD-related symptoms. 
 Of other AD-related and demographic characteristics, younger age (van der Vlies et al., 
2009; Lopez et al., 2010; Musicco et al., 2010; Sakurai et al., 2011; Ito et al., 2011; Sona et al., 
2013), higher education (Musicco et al., 2010; Sakurai et al., 2011), and more severe 
dementia at baseline (Lopez et al. 2010; Zhou et al., 2010; Sona et al., 2013) have been 
associated with a rapid cognitive decline. As indicated in the review of Sona et al., 2013, 
these characteristics were consistently associated with a rapid progression of the disease, 
even though opposite results have been obtained as well (Rabins et al., 2013; Grønning et 
al., 2012; Cosentino et al., 2006; Rountree et al., 2012). Accordingly, younger and highly 
educated persons with more severe AD at baseline seem to have a worse prognosis. The 
impact of education on the progression rate of the symptoms may be different before and 
after a certain phase. According to Hall et al. (2007), formal education delayed the time 
when the memory decline accelerated, but after the acceleration had started, the rate of 
decline increased with additional years of education. The findings concerning the impact of 
gender on rapid symptom progression have been contradictory; both male (Zhou et al. 
2010; Ito et al., 2011; Rountree et al., 2012; Sona et al., 2013) and female gender (Rabins et al., 
2013) have been found to predict a rapid symptom progression. Furthermore, the number 
or severity of neuropsychiatric symptoms at baseline (Wilson et al., 2006; Buccione et al., 
2007; Lopez et al., 2010; Palmer et al., 2011; Rabins et al., 2013), especially psychotic ones 
(Buccione et al., 2007; Wilkosz et al., 2010) has been associated with a rapid symptom 
progression.  
 On the basis of their consensus papers and reviews, Soto et al. (2008) and Schmidt et al. 
(2011) argue that there is a need to define rapid decliners more clearly. Though they 
acknowledge the limitations of the MMSE, they both suggest that the loss of three or more 
points in the MMSE within six months or six points within a year should be used in clinical 
practice as an indicator of a rapid decline. 
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2.3 MEASURING THE PROGRESSION OF SYMPTOMS IN ALZHEIMER’S 
DISEASE 
2.3.1 Progression of cognitive decline, measured with the CERAD Neuropsychological 
Battery and the Mini-Mental State Examination 
The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) was founded in 
the 1980s to develop standardised measures for the assessment of AD. The CERAD 
Neuropsychological Battery (CERAD-NB) was developed to measure early cognitive 
impairment in AD (Welsh et al., 1994), and later studies have supported the use of the 
CERAD-NB as a reliable measure for screening AD-related cognitive deficits (Fillenbaum et 
al., 2008; Sotaniemi et al., 2012; Wolfsgruber et al., 2013). In Finland, the CERAD-NB was 
introduced in 1999, and as in some other countries, it has been established as a screening 
tool for memory disorders in primary health care for persons of 55 and older (Hänninen et 
al., 1999; Sotaniemi et al., 2012).  
 The CERAD-NB has been compiled from previously published tests measuring cognitive 
domains known to become impaired in the course of AD. The original test battery includes 
subtests that measure naming skills, verbal fluency, verbal learning, delayed recall, delayed 
recognition, and visuospatial skills (constructional praxis) (Welsh et al., 1994). As additions 
to the Finnish version (Hänninen et al., 1999), there is a test of delayed recall of visual items 
(constructional praxis delayed recall) and a clock-drawing test (Freedman et al., 1994). The 
measures of episodic memory in particular have been efficient in distinguishing normal 
aging from early AD (Welsh et al., 1991, 1992; Sotaniemi et al., 2012). Individual CERAD-
NB subtests have also been used to distinguish the stages of AD dementia in cross-sectional 
studies, but there is a lack of follow-up data on the CERAD-NB subtests for persons with 
AD.  While memory tasks have not been found effective (Welsh et al., 1991; Barth, et al. 
2005) in distinguishing the stages of dementia, the best individual subtests have been verbal 
fluency (Welsh et al., 1992; Bertolucci et al., 2001; Barth et al., 2005) and praxis (Welsh et al., 
1992; Barth et al., 2005). Recognition memory (Welsh et al., 1992) and the Boston naming 
test (Bertolucci et al., 2001) have also effectively classified the severity of dementia in cross-
sectional studies. 
 Recent studies have also shown that the CERAD-NB total score, which was developed 
later (Chandler et al., 2005), is a valid and useful tool both for screening (Paajanen et al., 
2013) and for monitoring the progression of symptoms in AD-related dementia (Rossetti et 
al., 2010). Significant differences have been observed in the CERAD-NB total scores across 
different stages of dementia (Seo et al., 2010), and also significantly greater annual changes 
in the CERAD-NB total scores for AD patients than for the controls (Rossetti et al., 2010). 
Annual changes in the CERAD-NB total score correlate significantly with the severity of 
dementia and the person’s functional ability (Rossetti et al., 2010).  
 The whole CERAD-NB is often too time-consuming to be used in clinical settings as a 
follow-up tool for the progression of AD. On the other hand, the commonly used MMSE 
(Folstein et al., 1975) has been claimed to be of limited value as an instrument for screening 
(Mitchell, 2009) and measuring the progression of AD-related symptoms (Atchinson et al., 
2004; Clark et al., 1999). In a meta-analysis Mitchell et al. (2009) noted that the MMSE had 
restricted value for diagnosing MCI against healthy controls and a limited capability of 
helping to identify cases of Alzheimer's disease against MCI. They suggest that the MMSE 
offers modest accuracy for ruling out a diagnosis of dementia in primary care but that for 
all other purposes it should be combined or replaced with other methods. The MMSE has 
been claimed to have a large measurement error and substantial variation in the annual 
scores measuring the progression of AD symptoms (Clark et al., 1999). As the early 
detection of AD has been the main focus of research, more information and more reliable 
measures for assessing cognitive deficits during the course of AD are needed.  
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2.3.2 Clinical rating of dementia, activities of daily living, and the Neuropsychiatric 
Inventory 
Staging the severity of AD with global measures is a common and useful practice in both 
clinical and research settings for many reasons (O’Bryant et al., 2008). The Clinical 
Dementia Rating Scale (CDR), a scale based on a semi-structured interview, was developed 
for this purpose in the 1980s (Hughes, 1982; Morris et al., 1993). It is a commonly used 
instrument that provides a global score (questionable, mild, moderate, or severe dementia) 
and a more detailed quantitative index, the CDR sum of boxes score (CDR-sb). It combines 
information obtained from the caregiver or other informant with that obtained from the 
person with AD, and the scale tracks the change from the person’s previous level as a cause 
of cognitive problems.   
 Alzheimer Disease Cooperative Study Activities of Daily Living (ADCS-ADL) (Galasko 
et al., 1997) is a commonly used measure of daily functions in clinical trials (Ard et al., 
2013), but functional ability has also been assessed with a variety of other measures in AD 
studies (Table 2). In Finland, the ADCS-ADL measure is commonly a part of the diagnostic 
procedures (Memory disorders: Current Care Guidelines, 2014). It includes questions about 
the basic and instrumental activities of daily living, and the real functioning of the person 
with AD in different tasks of everyday life is rated by a caregiver or other informant.  
 The neuropsyciatric inventory (NPI) (Cummings et al., 1994) is the most widely used 
scale for assessing behavioural and psychological problems (neuropsychiatric symptoms, 
NPS) in cognitive disorders, allowing the assessment of a broad spectrum of 
neuropsychiatric symptoms (Dillon et al., 2013). It is a structured interview designed to 
obtain data from the caregiver or other informant. The NPI includes twelve behavioural 
and psychological domains that are typically related to AD:  delusions, hallucinations, 
agitation, anxiety, depression, apathy, irritability, euphoria, motor behavior, sleep 
disturbances, and appetite disturbances. 
  
2.4 INTERVENTIONS FOR DELAYING NURSING-HOME PLACEMENT 
Due to increasing costs of dementia care and treatment and a lack of disease-modifying 
medication for AD, different kinds of interventions have been developed to delay nursing-
home placement or affect the wellbeing of persons with AD and their caregivers (Table 4). 
The results of these studies, however, have been contradictory. Meta-analyses and reviews 
of various interventions and several outcome measures suggest that specific interventions 
work on specific targets and that only multicomponent interventions have succeeded in 
delaying institutionalisation. Studies on multicomponent interventions are limited in 
number, but they have been analysed in several meta-analyses (Pinquart & Sörensen, 2006; 
Olarazan et al., 2010; and de Vugt & Verhey, 2013).  
 
2.4.1 Multicomponent interventions to delay nursing-home placement  
In the review by Olazaran et al. (2010), different kinds of non-pharmacological 
interventions were evaluated. By pooling three high-quality randomised and controlled 
trials (Lawton et al., 1989; Mittelmann et al., 1993, and Belle et al., 2006) that had tested 
multicomponent interventions for the caregivers, the reviewers showed that by means of 
such interventions a delay had been attained in the institutionalisation of persons with mild 
to moderate AD. The essential components of these interventions were individual 
assessment, information, counselling, and support. Also, the role of skill training, respite 
services, support groups, and continuous availability of a therapist was emphasised. 
Similarly, the review by Pinqart & Sörensen (2006) also evaluated a range of interventions 
targeted to caregivers of persons with AD or dementia in general. A delaying effect on 
institutionalisation emerged only for the structured multicomponent interventions, but the 
long-term effects were impossible to assess. The multicomponent interventions combined 
different forms of intense intervention such as education, support, and respite. Pinqart & 
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Sörensen (2006) remark that the reasons why other interventions lacked effect may have 
been that some interventions prepared the caregivers for institutionalisation, that the 
dosage of many interventions may have been too low, and that even the best interventions 
have only a limited effect on some stressors, such as the progression of AD.  
 The review by van Mierlo et al. (2010) indicated that personal characteristics such as the 
type and severity of dementia, gender, and the presence of behavioural or mental health 
problems were connected with intervention outcomes. Of caregiver characteristics, being 
female and a spouse was associated with a longer delay in institutionalisation (Pinquart & 
Sörensen, 2006). Four of the studies examined showed delayed nursing-home placement of 
persons with mild to moderate AD or other dementia (van Mierlo et al., 2010); these studies 
were partly the same as cited above: a training programme for dementia caregivers 
(Brodaty et al., 1997), individual and family counselling (Mittelman et al., 1996), meeting-
centre support programme (Dröes et al., 2004), and reality orientation therapy (Metitieri et 
al., 2001). In the studies reported by Dröes et al. (2004) and Metitieri et al. (2001), however, 
the samples were small and not randomised. 
 
2.4.2 Interventions focused on specific targets 
In a review focusing on cognitive reframing for family carers (Vernooij-Dassen et al., 2011) 
no effects were found on institutionalisation or caregiver-related measures, even if the 
intervention seemed to reduce the subjective stress of the caregiver. This is in line with the 
results of Pinqart & Sörensen (2006). The authors conclude that cognitive reframing may be 
an effective component of individualised multicomponent interventions (Vernooij-Dassen 
et al., 2011). Caregiver interventions also showed positive immediate effects of small-to-
medium sizes on factors such as dementia caregivers’ burden, depression, and 
ability/knowledge, and the results were considered to have practical significance, too 
(Pinquart & Sörensen, 2006). The long-term effects could not be evaluated, however, and 
many intervention effects were specific to particular outcomes.  
 Occupational interventions have been found to delay functional disability (McLaren et 
al., 2013), and some results encourage the use of cognitive stimulation for general cognitive 
enhancement (Spector et al., 2012). Interventions for behavioural symptoms have also 
yielded promising results (Spira & Edelstein, 2006). 
 
2.4.3 Recent intervention studies with no positive effects found 
Although some multicomponent interventions have been reported to delay 
institutionalisation, recent studies by Brodaty et al. (2009) and Phung et al. (2013) found no 
long-term effects of psychosocial intervention on nursing-home placement or on other 
outcome measures. In the study by Brodaty et al. (2009), caregivers in the treatment group 
received individual and family counselling sessions. Ad hoc counselling by telephone was 
available on demand for up to two years. The authors point out that there were several 
important differences between this study (Brodaty et al., 2009) and the previous one, in 
which they found positive intervention effects (Mittelman et al., 1999). The participants in 
the later study were less impaired, ad hoc counselling was available for a shorter period, 
the participants were treated with AD-targeted medication (donepezil), and general 
awareness, expectations, and mainstream treatments were somewhat different in the later 
decade. The authors suggest that for better outcomes, the interventions should meet the 
needs of the participants better. They also remark that issues of the availability and 
affordability of community care may keep patients at home a longer time and that 
differences in community care between countries may cause differences in intervention 
results. In the study by Phung et al. (2013), a multifaceted semi-tailored psychosocial 
intervention programme targeted to persons with recently diagnosed mild AD or Lewy 
Body dementia had no long-term effects (in a three-year follow-up) on any patient-related 
or caregiver-related outcome measure or on institutionalisation. The intervention included 
counselling, information, and support for persons with dementia and their caregivers. 
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Individual counselling sessions, group courses, and telephone contacts were arranged for 8-
12 months. Even though there were no quantitative results, almost all persons with AD and 
their caregivers in the intervention group found the programme beneficial. The authors 
remark that in planning the support, the needs of persons with AD and their caregivers 
should be assessed and that regular follow-up is important for identifying the emerging 
needs that require intervention. The type, dosage, intensity, and duration of early 
intervention should probably be better tailored to match the needs of the persons with AD 
and their caregivers. Contradictory results in different studies may be caused by differences 
in population selection or in intervention procedures. Furthermore, the time the study was 
carried out is probably significant, for diagnostic procedures, treatment and care, 
knowledge, and attitudes change. 
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3 Aims of the Study 
This doctoral dissertation aimed at assessing the clinical features of persons with very mild 
or mild AD in a three-year follow-up started after diagnosis and at evaluating the 
suitability of the Consortium to Registry for Alzheimer’s Disease Neuropsychological Test 
battery (CERAD-NB) (Welsh et al., 1994; Hänninen et al., 1999) for use in measuring the 
progression of cognitive deterioration in AD. More specifically, the aims of the studies 
forming the basis of this dissertation were as follows: 
 
1. To find out whether global cognitive performance assessed with the CERAD-NB total 
score is associated with the severity of dementia, activities of daily living, and 
neuropsychiatric symptoms in persons very mild or mild AD. (Study I)  
 
2. To examine the changes in cognition, activities of daily living, neuropsychiatric 
symptoms, and the severity of AD over a three-year follow-up of persons with very mild or 
mild AD at baseline. An additional aim was to examine whether the CERAD-NB total score 
is a suitable instrument for monitoring cognition in following up persons with very mild 
and mild AD. (Study II) 
 
3. To find out which CERAD-NB subtests and which combination of subtests are the best 
indicators of changes in the severity of AD during the three-year follow-up. A further aim 
was to investigate the possibility of predicting the progression of AD symptoms by means 
of baseline demographic and CERAD-NB subtest information. (Study III) 
 
4. To examine the efficacy of an extended psychosocial intervention programme 
administered to persons with very mild or mild AD and their family caregivers during the 
first two years after diagnosis. (Study IV) 
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4 Subjects and Methods 
4.1 STUDY DESIGN  
All the four studies were part of the ALSOVA Project, which was a prospective, 
randomised and controlled follow-up study of persons with AD and their caregivers. The 
main aim of ALSOVA was to evaluate the effectiveness of early psychosocial intervention 
on the institutionalisation of persons very with mild or mild AD at baseline, the 
progression of AD in normal care, the wellbeing of the caregivers, and the impact of AD 
care on health economics. A total of 241 volunteering patient-caregiver dyads from three 
municipalities in Finland were recruited after they had received an AD diagnosis in 2002-
2006, and the dyads were monitored annually for up to five years. Due to issues in the 
availability of the data and the drop-out rates, the present studies are based on three-year 
follow-up data. 
 The first annual study visit was arranged soon after the AD diagnosis (five months later 
on average). The caregiver was interviewed by a study nurse and the person with AD was 
evaluated and interviewed by a psychologist. The extended data collected included age, 
gender, education, physical health, medication, household composition, living 
arrangements, wellbeing, caregiver burden, and the utilisation of society resources (for 
details, see Välimäki, 2012). The dates of institutionalisation and death were verified from 
the medical records, also for those participants who dropped out during the three-year 
follow-up period.  
 The subjects were randomised into a psychosocial intervention group and a control 
group (1:2) at the time of the baseline visit (for Study IV). The lots were drawn by a study 
nurse who otherwise took no part in the study. The psychosocial intervention, totalling 16 
days, was carried out at the Brain Research and Rehabilitation Center Neuron during the 
first two years after the diagnosis (Appendix, Study IV, Figure 1). It included programmes 
for both the persons with AD and their caregivers. They had opportunities to discuss their 
life situation. To provide them with information about AD and the social services available, 
lectures were given by neurologists and a social worker. Group discussions were organised 
for the persons with AD and their caregivers separately. The domain of stress reduction 
was addressed by means of a variety of creative activities. During the intervention, both the 
persons with AD and their caregivers were encouraged to engage in physical exercise. The 
final meeting included a social activity, which was intended to encourage the persons with 
AD and their caregivers to engage in social activities such as concerts. The patient-caregiver 
dyads remained the same for the two-year intervention period. The goal was to support 
networking among them. Altogether, 11 course groups were arranged. A maximum of 10 
families were invited to each course. The control group was followed up annually in a way 
similar to that for the intervention group except that it did not receive the psychosocial 
intervention. 
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Figure 1. The study design 
Screening 
241 participants 
 
Baseline 
For 234 
participants, all 
data available 
Baseline 
For 2 participants, 
partial data 
available 
3 participants      
did not meet the 
inclusion criteria 
(CDR=2) 
Visit 1            
(12 months)       
For 4 participants, 
partial data 
available 
Visit 1            
(12 months) 
For 194 
participants, all 
data available 
Visit 3            
(36 months) 
For 125 
participants, all 
data available 
 
38 participants 
dropped out 
Visit 2            
(24 months)       
For 5 participants, 
partial data 
available 
1 participant did 
not attend this 
visit but attended 
the next year 
Visit 3            
(36 months)       
For 6 participants, 
partial data 
available 
 
29 participants 
dropped out 
 
38 subjects 
dropped out 
Visit 2            
(24 months)  
For 163 
participants, all 
data available 
2 participants               
did not meet the 
inclusion criteria                     
(not AD, or impaired 
vision) 
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4.2 PARTICIPANTS 
The participants were diagnosed by a geriatrician or a neurologist at their local clinics in 
accordance with the NINCDS-ADRDA (McKhann et al., 1984) and DSM-IV (American 
Psychiatric Association, 1994) guidelines. The diagnostic procedure included brain imaging 
(CT or MRI), different diagnostic laboratory tests, and a neuropsychological examination. 
 The criteria of inclusion in the ALSOVA follow-up study were that the participants had 
been diagnosed with very mild or mild AD at baseline, were fluent in Finnish, community-
dwelling, were free of co-morbid conditions that could have affected their cognition at 
baseline, and were able to do the CERAD-NB at baseline. In the Alsova Study, the 
endpoints were institutionalisation and/or death. Out of the 241 participants screened, one 
was excluded at the baseline visit on account of unconfirmed AD. Three participants were 
excluded on account of having moderate AD (Clinical Dementia Rating, CDR=2) at baseline 
and one on account of impaired vision. The final study population comprised 236 voluntary 
participants. The ALSOVA research design is presented in Figure 1. To be included in the 
Alsova Study, the participants had to have a family caregiver who was in daily contact with 
them. The caregiver could be the spouse (n=166), a child, a sibling, a son- or daughter-in-
law, or another close relative. In addition to the annual study visits, the participants 
received treatment in their regular health care system. The use of AD-targeted medication 
was recommended, and the participants might have been using other medication as well.  
 In Study II, only those participants were included for whom the CERAD-NB results and 
caregiver interview data were available from the baseline visit and all the three follow-up 
visits. Besides, only those participants were included who had an MMSE score of < 18, 
which had been set as the cut-off point for mild AD. Thus a total of 115 subjects were 
included in Study II. The numbers of participating subjects and the data collected in Studies 
I-IV are presented in Table 5. 
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4.3 MEASUREMENTS 
4.3.1 Assessment of cognition 
Cognition was evaluated with the CERAD-NB (Welsh et al., 1994) and the Mini-Mental 
State Examination (Folstein et al., 1975). The CERAD-NB is a test battery compiled from 
previously published tests measuring cognitive domains known to be impaired in AD. For 
each subject, the CERAD-NB total score was calculated with the subtest addition method 
(range 0-100) (Chandler et al., 2005). The Finnish version of the CERAD-NB included all 
subtests from the original English test battery: the Boston naming test (15-item version; 
range 0-15), verbal (category) fluency (animals; range from 0 to no limit), word list learning 
(range 0-30), word list recall (range 0-10), word list recognition (range 0-20), and 
constructional praxis (range 0-11). In addition, the Finnish version included the clock-
drawing test (range 0-6) and the constructional-praxis delayed recall test (range 0-11) 
(Hänninen et al., 1999).  
 Verbal fluency is a measure of verbal production, semantic memory, and language skills, 
and it also requires executive function skills. The Boston naming test is a test of visual 
naming, revealing word-finding difficulties. The word list learning task measures the 
ability to learn new verbal information and to recall it later, both freely and with cues: The 
score of the word list recall test measures the amount of verbal information retained over 
the delay interval, and the word list recognition test measures the recognition and 
discrimination of the words presented earlier. The constructional-praxis task measures 
visuospatial and constructional abilities, and constructional praxis recall is a measure of 
delayed visual memory. The clock-drawing test measures visuospatial and constructional 
skills, and planning and executive function skills are also covered. (Welsh et al., 1994; 
Pulliainen et al., 1999) 
4.3.2 Assessment of the severity of dementia  
The severity of AD was measured with the Clinical Dementia Rating (Hughes et al., 1982; 
Morris, 1993). The CDR is a semi-structured interview, which includes six areas: memory, 
orientation, judgement and problem-solving, community affairs, home and hobbies, and 
personal care. Each area is scored from zero to three, and the scores are added up to 
produce the CDR Sum of Boxes (CDR-sb) score (range 0-18) and a global score indicating 
the stage of dementia (0=no dementia, 0.5=very mild, 1=mild, 2=moderate, 3=severe). The 
stages of dementia can also be assessed in terms of the CDR-sb score as follows: 0=normal, 
0.5-4.0=questionable cognitive impairment, 3.0-4.0=very mild dementia, 4.5-9.0=mild 
dementia, 9.5-15.5=moderate dementia, and 16.0-18.0=severe dementia (O’Bryant et al., 
2008).  In Study III, the CDR-sb score was used as an outcome measure. 
 At the time of the baseline visits, the subjects were classified into those with very mild 
AD (CDR=0.5) and those with mild AD (CDR=1) on the basis of the CDR interview in 
accordance with clinical practice. Later on, the Washington University CDR-assignment 
algorithm was used (www.alz.washington.edu/cdrnacc.html). Thus, before analysing the 
data for Study III, all the CDR global scores were re-calculated, and the classification of 48 
borderline cases was changed. This did not affect the CDR-sb scores. 
4.3.3 Other measures 
Functional ability was assessed with the Alzheimer’s Disease Cooperative Study – 
Activities of Daily Living Inventory (ADCS-ADL, range 0-78) (Galasko et al., 1997), which is 
a set of informant-based items describing the performance of ADL by persons with AD. A 
caregiver is asked to evaluate 23 basic (e.g., eating, walking) and instrumental (e.g., 
finances, household chores) activities of the daily living of the person with AD during the 
past four weeks. For each domain, the informant is to indicate the level of functioning, e.g., 
whether the person with AD functions independently, with supervision, or with assistance.  
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 Behavioural and psychological symptoms were evaluated with the Neuropsychiatric 
Inventory (NPI) (Cummings et al., 1994). It is an informant-based interview, which assesses 
twelve behavioural disturbances occurring in persons with dementia: delusions, 
hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, 
apathy/indifference, disinhibition, aberrant motor behaviour, sleep and night-time 
behaviour, and appetite and eating disorders. The NPI is designed to assess the changes 
that have appeared in the person’s behaviour since the onset of AD. Each domain includes 
subquestions, which provide examples of the disturbance in question. If a behaviour is 
present, its frequency (occasionally, often, frequently, very frequently) and severity (mild, 
moderate, severe) are indicated. The total NPI score is the sum of the subscale scores 
(frequency x severity, range 0-144). Higher scores indicate more severe behavioural 
disturbance. 
 The effect of early psychosocial intervention on the quality of life of persons with AD 
was assessed with the disease-specific QoL-AD (Quality of life in Alzheimer’s Disease 
Scale) and the VAS (Visual Analog Scale) wellbeing and life satisfaction instrument. The 
QoL-AD is a 13-item measure specifically developed for use with persons with AD and 
their caregivers (Logsdon et al., 1999).  The maximum score (indicating high QoL) is 52 and 
the minimum 13.  The 10-cm VAS scale is a one-item indicator of QoL, including a single 
question of the general wellbeing of the person on a scale of 0 (worst possible) to 100 (best 
possible).  
4.4 STATISTICAL ANALYSES 
Statistical analyses were performed by using SPSS (SPSS Inc., Chicago, Ill., USA). In Studies 
III and IV, use was also made of STATA (StataCorp, Texas, USA). The level of statistical 
significance was set at p<0.05. To summarise the data, descriptive statistics (means, 
standard deviations, medians, percentages, etc.) were used. To analyse the differences 
between groups (genders, CDR 0.5 or 1 at baseline, different intervention groups, and 
participants with three-year follow-up data vs. dropouts), either independent-samples t-
tests or Mann-Whitney U-tests were used, depending on the normality of the distribution 
of the variable. To analyse the group differences in dichotomic variables, the chi-square test 
was used. To analyse the relations among the variables, either Pearson’s product-moment 
correlation or Spearman’s rank-order correlation was used, depending on the normality of 
the distribution. 
 In Study II, linear regression models adjusted for age, gender, and education were 
created to evaluate the association between the CERAD-NB total score and the other 
efficacy parameters and the severity of AD at the baseline visit and at the three-year follow-
up visit, and also to study the effect of education on the CERAD-NB total score. For the 
regression models, covariates with significance less than 0.2 in univariate analyses were 
selected. To estimate the significance of change in each efficacy parameter between the 
follow-up visits, a paired-samples t-test was used.   
 In Study III, to determine which CERAD-NB subtests and demographic variables and 
which subtest combination were the most associated with the severity of AD (CDR-sb), 
Generalised Estimating Equation (GEE) models were made use of, together with repeated 
measures of CERAD-NB subtests and CDR-sb. Also, baseline subtest data was used to 
predict the severity of AD (repeated measures of CDR-sb). All GEE models were specified 
with a Gaussian distribution, identity link function, and an unstructured correlation matrix. 
To compare the power of the models and determine how much of the variation in the 
outcome was explained by the models, goodness-of-fit diagnostics and pseudo-R2 statistics 
(Twisk, 2013) were used. A detailed explanation of the creation and selection of the models 
is to be found in the original research article (Appendix, Study III). 
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 For Study IV, an appropriate sample size was determined on the basis of the primary 
outcome measure (i.e., nursing-home placement). A target size of about 240 (with a 1:2 
randomisation) was estimated to ensure 80-% power and a significance level of 0.05 to 
detect an approximate 20-% difference between the study groups after the three-year 
follow-up. The differences in the rates of nursing-home placement between the control 
group and the intervention group were evaluated with the proportional subhazard (sHR) 
regression model to adjust the impact of a competing risk (i.e., death) on the cumulative 
risk of institutionalisation over the 36-month follow-up. The regression estimates were 
adjusted for age, gender, and education. The differences in the mortality rates between the 
control group and the intervention group were analysed with the Cox hazard ratios. The 
differences in secondary outcomes between the control group and the intervention group 
were analysed as adjusted annual mean changes from the baseline. Use was made of the 
Linear Mixed Model (LMM) with a repeated-measures structure, Gaussian distribution, 
identity link function, and an unstructured correlation matrix. 
4.5 ETHICAL CONSIDERATIONS 
The protocol of the ALSOVA Study was approved by the ethical committee of Kuopio 
University Hospital (No. 64/00). All potential participants were informed about the 
procedures of the study orally and in in writing. The voluntariness of participation and the 
confidentiality of the data to be collected were emphasised. An Informed Consent Form 
was signed by each participating person with AD and each caregiver. The caregiver also 
provided a proxy consent on behalf of the person with AD. 
 All the four studies (I-IV) were conducted as part of the ALSOVA Study. I participated in 
the data collection as a psychologist in the years 2006 to 2011 and was involved in the 
recording and processing of the data. As to Studies I, II, and III, I planned the research 
designs and was in charge of the statistical analyses and the interpretation of the data 
under the guidance of my supervisors. In these three studies I was the first author while the 
co-authors participated in the collection and processing of the data and furnished critical 
comments on the manuscripts. In addition, professional statistical consultation was made 
use of with the more complex analyses. In Study IV, I contributed to the interpretation of 
the data and the drafting of the manuscript. 
39 
 
5 Results 
5.1 GENERAL CHARACTERISTICS OF THE PARTICIPANTS IN THE 
ALSOVA STUDY  
Demographic characteristics of the participants in the four studies are presented in Table 6. 
Study I focused on the baseline data of the participants (n=236), who were then followed up 
for three years in Study III and Study IV. The CDR classification of some subjects was 
changed after re-calculations (see Methods, page 32). Study II includes the three-year data 
for the subgroup (n=115). The mean age of both the whole population and the subgroup 
(Study II) was 75.1, and the mean years of education were 7.6 for the whole population and 
7.8 for the subgroup. The age at baseline ranged between 53 and 90 years, but most of the 
participants (94.5 %) were 65 or older at the time of the baseline visit. In 70.3 % of the cases 
the caregiver was the spouse and in 23.7 % of the cases, a child of the person. The 
remaining 6 % of the caregivers were siblings or children’s spouses.   
 A small majority of the participants were women in both the whole population (51.3 %) 
and the subgroup of Study II (56.5 %). There was no difference at baseline in the CERAD-
NB total score, the MMSE, the CDR-sb, or the NPI score between the genders. Women 
performed better in the baseline ADCS-ADL than men (p<.001) (Study I, data not shown). 
In an adjusted regression model, gender was not associated with cognition (CERAD-NB 
total score) at baseline or at visit 3 (Table 4, Study II). There were some differences between 
men and women in CERAD-NB subtests during the three-year follow-up (Study III, data 
not shown). Men outperformed women in the Boston naming test at baseline (p<.001), at 
visit 1 (p=.022), and at visit 3 (p=.015). Men also outperformed women in the word list 
recognition test at visit 3 (p=.031). In contrast, women outperformed men in the word list 
learning test at baseline (p=.022) and in constructional praxis at visit 3 (p=.044). Women also 
had lower (i.e., better) CDR-sb scores than men at visit 1 (p=.026) and at visit 2 (p=.028). 
 On the basis of their CDR scores at baseline, the participants were classified into cases of 
very mild (the CDR 0.5 group) and mild dementia (the CDR 1.0 group). During the three-
year follow-up, both groups showed a notable prevalence of mild dementia (CDR=1). 
Figure 2 presents the annual proportions of CDR classes. In 20 cases out of the whole 
population, the CDR stage improved temporarily from the previous visit; however, all of 
these participants showed deterioration later in the follow-up. Eight participants in the 
CDR 0.5 group and 26 in the CDR 1 group were stable throughout the three-year follow-up. 
Forty-nine participants in the CDR 0.5 group and 26 in the CDR 1 group advanced to the 
next, more severe CDR stage during the three-year follow-up. Fourteen participants in the 
CDR 0.5 group and three in the CDR 1 group advanced by two CDR stages. Finally, three 
participants advanced by three CDR stages (from very mild to severe dementia). In the 
Study II subgroup (n=115), too, more than a half of the subjects still had very mild or mild 
AD after the three years. 
 In all the studies, the CDR 0.5 group and the CDR 1 group did not differ significantly in 
age. The CDR 0.5 group was slightly more educated in Study III (p=.004) and Study II 
(p=.012). However, this difference was not found in Study I, in which a different kind of 
CDR classification was used. Differences in the proportion of female subjects came close to 
reaching significance in the corrected data (p=.054) and in the subgroup of Study II (p=.088) 
but not in Study I (with a different CDR classification) (p=0.583). 
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Correlations among age, education, and clinical characteristics at baseline (n=236) (Table 2, 
Study I) and at the third follow-up visit (n=115) were analysed (Table 3, Study II). The 
length of education correlated with cognition at baseline (CERAD-NB total r=.334, p<.001; 
MMSE 0.278, p<.001) and at the third follow-up visit (CERAD-NB total r=0.257, p=.006; 
MMSE r=.0232, p=0.013), but no significant correlation was found between age and baseline 
cognition (table 2, study I). Also, in the subgroup of Study II (n=115), analysed with the 
adjusted regression model, education affected cognitive performance (CERAD-NB total 
score) both at baseline (p<.001) and at the third follow-up visit (p=.001), while age (baseline 
p=.135, visit 3 p=.350) and gender did not (baseline p=.785, visit 3 p=.870) (Table 4, Study II).  
 The verbal fluency and the clock-drawing test were the only subtests that did not 
correlate with education at any visit. Age correlated only with the naming-test scores 
(Study III, data not shown). 
 Age and education correlated with the ADCS-ADL (age r=-.201, p<.05, education r=.357, 
p<.001) and education with the CDR-sb scores (age r=.159, p=ns; education r=-.204, p<.05 at 
baseline, i.e., younger age and more years of education were related with better ADL, and 
more years of education with milder AD. The NPI did not correlate with age or education 
at baseline (Table 2, Study I).  
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Figure 2. Clinical Dementia Rating (CDR) classes of persons with very mild (CDR=0.5) or mild 
(CDR=1) AD at baseline during the three-year follow-up 
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5.2 DROP-OUT ANALYSIS 
During the three-year follow-up, a total of 106 participants dropped out of the study 
(Figure 1). The most common reasons for dropping out were institutionalisation (34/236), 
death (20/236), and deterioration of health (15/236) of the persons with AD. Other reasons 
included caregiver-related reasons (health, burden, death, or refusal, 20/236), refusal of the 
person with AD (8/236), and some other causes (9/236). The disease severity of the drop-
outs (CDR-sb) at baseline had been similar to that of the participants who continued 
through the follow-up (p=.155). However, those who dropped out had more severe 
cognitive impairments (CERAD-NB total p=.047, MMSE p=.033, the clock-drawing test 
p=.003) at baseline. The two groups did not differ in education (p=.667), age (p=.407), or 
other CERAD-NB subtest scores at baseline.  
 For Study IV, the participants were randomised into an intervention and a control group, 
with the intervention group receiving psychosocial intervention (see Methods, page 27). 
The drop-out rate in the control group was significantly higher (76 out of 152 as opposed to 
30 out of 84 in the intervention group, p=0.035). Nine participants (11 %) deceased from the 
intervention group and 18 (12 %) from the control group (age- and gender-adjusted 
HR=0.755 (95 % CI 0.323 to 1.766); p=0.517). The average time from dropping out to dying 
was 20.4 months (95 % CI 11.3-29.5 months). The participants who died at nursing homes 
died in 8.5 months on average (95 % CI 3.8-12.9 months) after nursing-home placement 
(Study IV).  
5.3 CORRELATIONS OF THE CERAD NEUROPSYCHOLOGICAL BATTERY 
WITH OTHER MEASURES (STUDY I) 
The year-to-year development of the participants’ clinical characteristics is presented in 
table 7. A minority of the participants (18.2 %) had no neuropsychiatric symptoms at the 
beginning of the study. Out of all subjects, 21.5 % had one symptom, 13.1 % had two, and 
47.0 % displayed symptoms in at least three different NPI domains. The most common 
neuropsychiatric symptoms were apathy (48.3 %), depression (36.4 %), and irritability (33.9 
%). The mean ADCS-ADL score was 64.53 at baseline (Table 6). The subjects with very mild 
AD (CDR 0.5) had better cognition (CERAD-NB total, p<.001; MMSE, p<.001), better 
activities of daily living (ADCS-ADL, p<.001), and fewer neuropsychiatric symptoms (NPI, 
p=0.028) than the subjects with mild AD (CDR 1).  
 Table 8 presents the correlations of the values of the main variables at baseline and in 
year 3. Cognition (CERAD-NB total, MMSE) correlated with the severity of AD (CDR-sb) 
and activities of daily living (ADCS-ADL). However, no correlation was found between 
cognition and neuropsychiatric symptoms (NPI). Instead, the NPI total score correlated 
with the severity of AD (CDR-sb) and activities of daily living (ADL).  
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Table 8. Correlations among test results at baseline and at the third follow-up visit.  
 CERAD-NB total 
Baseline Year 3 
MMSE 
Baseline Year 3 
CDR-sb 
Baseline Year 3 
ADCS-ADL 
Baseline Year 3 
MMSE 
   Baseline 
   Year 3 
 
.618 
 
 
 
.762 
       
CDR-sb 
   Baseline 
   Year 3 
 
.319 
 
 
 
-.627 
 
-.443 
 
 
-.643 
     
ADCS-ADL 
   Baseline 
   Year 3 
 
.250 
 
 
.484 
 
.314 
 
 
.394 
 
-.580 
 
 
-.817 
   
NPI 
   Baseline 
   Year 3 
 
.087  
 
 
-.061 
 
.049 
 
 
-.074 
 
.231 
 
 
.453 
 
.339 
 
 
.521 
  
 
Baseline values: n = 236, baseline CERAD-NB total n = 234, baseline CERAD-NB subtests n = 
235-236 
Year 3 values: n = 115, year 3 CERAD-NB total n = 113, year 3 CERAD-NB subtests n = 125-
126 
The coefficient used was either Pearson’s product-moment correlation or Spearman’s rank-order 
correlation, depending on the characteristics of the variable.  
Bold = p<.05 
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5.4 DECLINE IN COGNITION AND OTHER CLINICAL FEATURES DURING 
THE THREE-YEAR FOLLOW-UP (STUDY II) 
 
Cognition (i.e., the changes in the CERAD-NB total and the MMSE) and the activities of 
daily living (i.e., the changes in the ADCS-ADL) deteriorated and the severity of AD (i.e., 
the change in the CDR-sb) increased significantly (p<.02) every year (Table 2, Figure 1, 
Study II). The annual means and the means of annual changes in the whole data of the 
ALSOVA Study participants are presented in Tables 7 and 9.  
 Persons with very mild AD (CDR 0.5) at baseline had better cognition during the three-
year follow-up than those with mild AD (CDR 1) did, as shown in the CERAD-NB (p<.05 at 
all visits), but the MMSE did not distinguish between the two groups (p>.02) (Study II). In 
Study III, however, the larger sample brought out a difference in the MMSE that was 
statistically significant for the first and the second follow-up visit as well. Also, the CDR 0.5 
group had better activities of daily living (ADCS-ADL, p <.001 at all visits) and fewer 
neuropsychiatric symptoms during the follow-up than the CDR 1 group did (NPI, p<.05 at 
baseline and the second and third follow-up visit, p=.057 at the first follow-up visit) (Study 
II). The CDR 0.5 group had smaller changes in ADCS-ADL during the three-year follow-up 
(p=.027), but no differences in the progression rate of other measures were found (data not 
shown). Because the NPI scores were not normally distributed, the median values were also 
analysed. In Study II, the CDR 0.5 group exhibited a lower median value even at the third 
follow-up visit than the CDR 1 group did at baseline (data not shown). The same was noted 
for the whole population (data not shown).   
 All clinical characteristics, i.e., cognition (CERAD-NB total and MMSE), activities of 
daily living (ADCS-ADL), and neuropsychiatric symptoms (NPI), still correlated 
significantly (p<.001) with the severity of AD (CDR-sb) at the third follow-up visit (Table 8). 
Similarly to the results of the baseline visit, cognition correlated with the activities of daily 
living but not with neuropsychiatric symptoms at the third follow-up visit. However, the 
changes in cognition and in the NPI did correlate with each other (data not shown). The 
activities of daily living correlated with neuropsychiatric symptoms at the third visit also.   
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Table 9. Annual mean changes in the MMSE, the CERAD-NB total, the ADCS-ADL, and  
the NPI of persons with Alzheimer’s disease during the three-year follow-up.  
 Baseline – Year 1 Year 1 – Year 2 Year 2 – Year 3 
CERAD-NB 
 range 
 mean (SD) 
n = 193 
-28 – 17 
-5.32 (7.75) 
n = 162 
-32 – 9 
-5.91 (7.75) 
n = 124 
-31 – 11 
-5.52 (7.94) 
MMSE 
 range 
 mean (SD) 
n = 198 
-11 – 5 
-2.28 (3.22) 
n = 165 
-13 – 6 
-1.96 (3.23) 
n = 124 
-11 – 5 
-2.39 (2.83) 
CDR-sb 
 range  
 mean (SD) 
n = 198 
-3.5 – 8 
1.49 (1.92) 
n = 168 
-3 – 6 
1.59 (2.02) 
n = 127 
-3 – 10 
1.91 (2.18) 
ADCS-ADL 
 range 
 mean (SD) 
n = 198 
-40 – 14 
-6.94 (8.37) 
n = 168 
-44 – 20 
-8.08 (10.30) 
n = 130 
-31 – 7 
-8.03  (9.24) 
NPI 
 range 
 mean (SD) 
n = 197 
-16 – 32 
2.44 (8.65) 
n = 167 
-19 – 28 
3.54 (8.83) 
n = 129 
-21 – 33 
2.88 (9.83) 
 
CERAD-NB total = Consortium to Establish a Registry for Alzheimer’s Disease 
Neuropsychological test battery total score; MMSE = Mini-Mental State Examination; CDR-sb = 
Clinical Dementia Rating sum of boxes; ADCS-ADL = Activities of Daily Living – Alzheimer 
Disease Cooperative Study; NPI = Neuropsychiatric Inventory 
Mean = mean of annual change from previous visit; SD = standard deviation 
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Table 10 to be continued 
Table 10. Correlations of the CERAD-NB subtest results with the CERAD-NB total score,  
the MMSE, and the CDR-sb at baseline and at the third follow-up visit. 
 CERAD-NB total 
Baseline Follow-up 
MMSE 
Baseline Follow-up 
CDR-sb 
Baseline Follow-up 
Verbal fluency 
   Baseline 
   Follow-up 
 
.717 
 
 
.633 
 
.334 
 
 
.665 
 
-.210 
 
 
-.641 
Naming 
   Baseline 
   Follow-up 
 
.638 
 
 
.733 
 
.400 
 
 
.523 
 
-.147 
 
 
-.345 
Word List Learning 
   Baseline 
   Follow-up 
 
.713 
 
 
.847 
 
.435 
 
 
.674 
 
-.311 
 
 
-.534 
Word List Recall 
   Baseline 
   Follow-up 
 
.532 
 
 
.578 
 
.388 
 
 
.374 
 
-.234 
 
 
-.346 
Word List Recognition 
   Baseline 
   Follow-up 
 
.533 
 
 
 
.611 
 
.378 
 
 
.409 
 
-.223 
 
 
-.404 
Constructional Praxis 
   Baseline 
   Follow-up 
 
.442 
 
 
.478 
 
.351 
 
 
.458 
 
-.174 
 
 
-.485 
Praxis recall 
   Baseline 
   Follow-up 
 
.448 
 
 
.453 
 
.417 
 
 
.420 
 
-.280 
 
 
-.260 
The clock-drawing test 
   Baseline 
   Follow-up 
 
.439 
 
 
.620 
 
.462 
 
 
.604 
 
-.339 
 
 
 
-.488 
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Table 10. (Continued) Correlations of the CERAD-NB subtest results with the CERAD-NB total 
score, the MMSE, and the CDR-sb at baseline and at the third follow-up visit. 
 
Baseline values: n = 236, CERAD-NB total n = 234, CERAD-NB subtests n = 235-236 
Follow-up values: n = 115, CERAD-NB total n = 113, CERAD-NB subtests n = 125-126 
The coefficient used was either Pearson’s product-moment correlation or Spearman’s rank-order 
correlation, depending on the characteristics of the variable.  
In Study I, Bonferroni corrections were used.  
All correlations were statistically significant at p<.05. 
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5.5 THE CERAD NEUROPSYCHOLOGICAL BATTERY SUBTESTS AS 
INSTRUMENTS IN A FOLLOW-UP STUDY OF ALZHEIMER’S DISEASE 
(STUDY III) 
Performance in all the CERAD-NB subtests declined during the three-year follow-up 
period (Figure 1, Study III). At baseline, the CDR 0.5 group outperformed the CDR 1 group 
in the MMSE, the CERAD-NB total, the CDR-sb and most of the CERAD-NB subtests. 
Throughout the visits, the two groups were distinguished by differences in verbal fluency, 
the CERAD-NB total, and the CDR-sb scores. In the CDR 1 group, the word list recall, 
constructional praxis, and the clock-drawing test mean scores were higher at visit 3 than at 
visit 2. Verbal fluency and the clock-drawing test were the only subtests that did not 
correlate with education at any visit (Study III, data not shown.) The global cognitive 
measures (the CERAD-NB total and the MMSE) correlated with all subtests at baseline and 
at all follow-up visits (Table 10).  
5.5.1 The short version of the CERAD Neuropsychological Battery as a follow-up tool 
To discover the best subtest combination for AD follow-up, GEE-models were used. Table 
3, Study III, presents the GEE-models used, which incorporated the MMSE (Model 1), the 
CERAD-NB total score (Model 2), both the MMSE and the CERAD-NB total score (Model 
3), and the best CERAD-NB subtest combination (Model 4) for the purposes of modelling 
the severity of AD.  The best explorative model comprised gender, time, verbal fluency, 
word list learning, word list recall, constructional praxis, and the clock-drawing test (Study 
III, data not shown); that model explained the CDR-sb better than the model that included 
all the subtests. The model including only gender, time, verbal fluency, constructional 
praxis, and the clock-drawing test produced nearly the same pseudo-R2 estimate (i.e., 
explanatory power). The addition of the MMSE boosted the pseudo-R2 of the model, and 
education and age were included because they are commonly used covariants. With this 
method, the model including age, gender, education, the MMSE, verbal fluency, 
constructional praxis, and the clock-drawing test (Model 4, Table 3, Study III) was 
determined to provide the best results. Although Model 3, which combined the MMSE and 
the CERAD-NB total score, provided a better explanation of the variance in the CDR-sb 
than either Model 1 or Model 2, Model 4 produced an even higher pseudo-R2 estimate (i.e., 
better explanatory power).  This combination of the MMSE, three CERAD-NB subtests, and 
the covariates explained 62.1 % of the variance in the severity of dementia (measured in 
terms of the CDR-sb) during the three-year follow-up period.  
5.5.2 Predicting the progression of Alzheimer’s disease with the baseline CERAD 
Neuropsychological Battery subtests 
The baseline variables of the same models as were used to explain the severity of AD 
during the follow-up were used to predict the progression of AD symptoms. The model 
that included the baseline values of the MMSE, verbal fluency, constructional praxis, the 
clock-drawing test scores, and the covariates predicted the progression of CDR-sb during 
the three year follow-up period better than the MMSE alone, the CERAD-NB total score 
alone, or the combination of the MMSE and the CERAD-NB did (Table 4, Study III). The 
model that included only the baseline measurements had a pseudo-R2 value of 36.6 %. In 
addition to these subtests, naming ability was found to be a significant predictor in a 
univariate analysis (data not shown). 
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5.6 THE EFFECT OF EARLY PSYCHOSOCIAL INTERVENTION ON 
ALZHEIMER’S DISEASE (STUDY IV) 
5.6.1 The delaying effect of the intervention on institutionalisation 
No differences in the rate of institutionalisation were found between the intervention and 
the control group after the three-year follow-up. By the third follow-up visit, 18 of 84 
subjects (21 %) from the intervention group and 24 of 152 (16 %) from the control group had 
been placed in nursing homes. The adjusted sHR estimate for the difference in the rate of 
nursing-home placement between the intervention and the control group was 1.30 (95 % CI 
0.69 to 2.45).  
5.6.2 Effects of the intervention on symptoms related to Alzheimer’s disease  
At the follow-up visits, the intervention group performed worse than the control group in 
the CERAD-NB; their proxy-rated ADCS-ADL scores were also lower and their CDR-sb 
scores higher (Figure 3, Study IV, Appendix). No differences in the NPI were observed 
between the groups during the 36-month follow-up, nor were there any differences in the 
subjects’ quality-of-life measures (15D, QoL-AD, and VAS) (Figure 3, Study IV, Appendix). 
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6 Discussion 
6.1 PROGRESSION OF ALZHEIMER’S DISEASE SYMPTOMS DURING THE 
THREE-YEAR FOLLOW-UP  
6.1.1 Cognitive deterioration 
In Study II, the annual decline in the CERAD-NB total scores, varying between -5.3 and -5.9 
points in the different years, was slightly less than found previously (-7.2 points, Rossetti et 
al., 2010). It should be noted that according to Rossetti et al. (2010), the change in the 
CERAD-NB total scores should be over 10 points to represent a clinically meaningful 
change. However, Rossetti et al. (2010) also point out that decreases that fail to exceed a 
specific limit may not necessarily be insignificant. 
 There was no difference in the mean annual change of the CERAD-NB total score 
between the CDR 0.5 group and the CDR 1 group (CDR 0.5 and 1 at baseline), which is in 
line with a previous study by Rossetti et al. (2010). However, Rossetti et al. (2010) included 
persons with moderate AD at baseline, thus comparing groups of mild and moderate AD 
(CDR≥2 or <2). 
 In Study II, the annual deterioration of the MMSE test scores (with the loss varying 
between -2.0 and -2.4 points in the different years) was in line with those found in recent 
studies (Gillette-Guyonnet et al., 2011; Tschanz et al., 2011; Vellas et al., 2012; Handels et al., 
2013; Phung et al., 2013), and no acceleration of the cognitive decline was found during the 
three-year follow-up. Vellas et al. (2012) found that the decline was faster in the second 
follow-up year than in the first. They had collected a large body of data from several 
countries. However, as their data also included persons with moderate AD (MMSE 10-26), 
their results may not be representative of the first years of Alzheimer’s disease diagnosed at 
the mild stage, as is expected nowadays. In Gillette-Gyuonnet et al.’s study (2011), too, 
though other characteristics of the participants were quite similar to those in the present 
study in that AD patients on antidementia drugs were enrolled in memory clinics and 
followed up over four years, there was the difference that the cohort included persons with 
very mild to moderate AD. 
 The rate of cognitive decline varied widely from person to person. In this study, 26.0 % 
of those participants who went through the three-year follow-up were relatively stable (i.e., 
staying at the same CDR stage), and 63.4 % were still in the mild phase of the disease at the 
end of the study (CDR 0.5 or 1). One third of the participants had reached the moderate 
stage at the end of the study, and only six participants were at the severe stage of the 
disease. These results are in line with those reported previously (Cortes et al., 2008). The 
most common reasons for dropping out of this study was institutionalisation, death, and 
comorbidities; thus it was probably the persons with more advanced dementia that 
dropped out, as has been reported in the previous studies, too.  
 In this study, the CERAD-NB total score distinguished between the groups with very 
mild and with mild AD at baseline all through the follow-up period, while the MMSE did 
not (Study II). When the different cognitive domains were examined in more detail (Study 
III), it was found that at baseline all the CERAD-NB subtests distinguished the CDR 0.5 
group from the CDR 1 group but that at the last (third) follow-up visit the only differences 
found were in verbal fluency and the CERAD-NB total score. These results concur with 
those of previous cross-sectional studies (Welsh et al., 1992; Bertolucci et al., 2001; Barth et 
al., 2005). Although the typical first sign of AD is memory problems, other aspects of 
cognition, such as the executive function and visual perception, may provide better 
information for staging AD, as suggested by Welsh et al. (1992).  
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 In conclusion, the progression rate of cognitive symptoms was found to be similar to 
those found in recent reports. This progression seems to be similar regardless of the stage of 
dementia, at least in the first few years of the disease, yet variable from person to person.   
6.1.2 Increase in neuropsychiatric symptoms 
The Neuropsychiatric Inventory (NPI) mean score (8.9 points) obtained for the participants 
at baseline in Study I can represent several occasional mild symptoms, two moderate 
symptoms that occur weekly or one severe symptom, for example. A minority (18 %) of the 
persons with very mild or mild AD at baseline had no NPS. Lam et al. (2006) reported 
almost twice as many NPS (NPI score 16.3). The difference may be explained by the fact 
that they included persons with mild to moderate AD in their study. In Study I, almost a 
half of the participants (47.0 %) displayed at least three different symptoms. The most 
common symptoms were apathy and depression, as had been found in previous studies 
(Serra et al., 2010; Dillon et al., 2013). In the present study, the annual change in the NPI 
score (between +2.4 and +3.5 points) represents one new symptom that occurs weekly or the 
worsening of one previously displayed symptom, for example. These findings are in line 
with those reported previously (Tschanz et al., 2011).  
 It has been emphasised recently that unlike previously thought, NPS are common at the 
early stage of the disease already (Lyketsos et al., 2011; Dillon et al., 2013). As NPS are 
emotional and behavioural manifestations, they are often more difficult for persons with 
AD, caregivers, and professionals to deal with than memory loss is. A person with AD may 
feel depressed and distressed and be irritable or abusive towards caregivers, for example 
(Dillon et al., 2013; Kales et al., 2013; Välimäki et al., 2014).  
6.1.3 Decline in activities of daily living in relation to the progression of AD  
For the whole population of this study, an annual decrease of 7-8 points was found in the 
measure of the activities of daily living (ADCS-ADL). A decline of this magnitude can be 
seen to represent a need of increased supervision or a one-level functional decline in 7-8 
domains of daily functions, or the total loss of two activities, for example. The result 
corresponds to the findings of Phung et al. (2013), who found a loss of 22.3 points (control 
group) and 26.7 points (psychosocial intervention group) over a three-year follow-up. Also, 
an annual loss of one activity by one half of the sample of persons with AD has been 
reported in previous work (Gillette-Gyuonnet et al., 2011). 
 Persons with late-onset AD in particular have comorbidities that affect their functional 
abilities (American Psychiatric Association, 2013), and the ADCS-ADL measure (Galasko et 
al., 1997) does not specify whether the decline of functional abilities is caused by cognition 
or physical problems. Instead, the CDR-sb may be seen as a global score to describe a 
person’s deficits in carrying out daily functions due to cognitive deterioration and the 
change in cognition and daily functioning from the person’s previous level. In this study, 
the annual changes in the CDR-sb scores varied between +1.5 and +1.9 points. Previous 
studies have reported annual increases of +1.44 points in the CDR-sb scores (Tschanz et al., 
2011) and increases of +4.17 points over 2 years (Cortes et al., 2008). 
 In conclusion, the progression of the three essential domains of AD, i.e., cognition, 
neuropsychiatric symptoms, and the activities of daily living, found in this study was quite 
similar to that reported in recent literature.  
6.1.4 Differences in the progression of symptoms between the group with very mild and 
the one with mild Alzheimer’s disease at baseline 
As expected, the CDR 0.5 group (= very mild AD at baseline) showed better global 
cognition (as measured with the CERAD-NB) and daily activities (ADCS-ADL) and fewer 
neuropsychiatric symptoms (= lower NPI) than the CDR 1 group (= mild AD at baseline) 
throughout Study II. A slower decline in the daily activities was observed in the CDR 0.5 
group, which was also found to be somewhat more highly educated. There are very few 
55 
 
reports in the literature that compare the long-term progression of AD-related symptoms in 
groups with very mild and ones with mild AD, but Nourashemi et al. (2008) report findings 
similar to those found in this study. The CDR 0.5 group also displayed fewer NPS 
throughout the three-year follow-up than the CDR 1 group had displayed at baseline. 
 There might have been some basic differences between the groups, or else, the early start 
of treatment and care might have affected the progression of AD-related symptoms. In 
addition to the possible benefit of AD-targeted medication, the persons with AD in the 
CDR 0.5 group and their caregivers started getting information and support earlier. It is 
also possible that the progression rate accelerates at some point in the disease and that the 
CDR 0.5 group were to reach this point only after the three-year follow-up was over.  
6.1.5 Association of the CERAD Neuropsychological Battery with other measures of the 
progression of Alzheimer’s disease  
 In Study I the cognition of persons with AD was significantly associated with ADL, 
which was consistent with previous findings obtained with the CERAD-NB total score (Seo 
et al., 2010) or other cognitive measures (e.g., Tractenberg et al., 2005; Bowens et al., 2009). 
An association was also found between ADL and neuropsychiatric symptoms, which was 
in line with the results of many other studies (e.g., Peters et al., 2006; Okura et al., 2010). 
These correlations tended to exist throughout the three-year follow-up (Study II). In the 
literature, most reports have indicated that behavioural symptoms and cognition are not 
directly related (Dillon et al., 2013). Changes in behavioural symptoms have been found to 
be independent from changes in cognitive measures (Tractenberg et al., 2005), but opposite 
results have also been reported (Serra et al., 2010). In this study, NPS did not correlate with 
cognition (as measured with the MMSE and the CERAD-NB total score) at baseline, nor did 
they correlate at the third follow-up visit, but the rates of the decline of both did correlate. 
Although the correlations between cognition and other clinical characteristics were modest 
at best, they were clearly significant. In contrast, the correlations between cognition and 
NPS did not even come close to significance. One may thus conclude that cognition and 
neuropsychiatric symptoms are independent manifestations of AD, even if they progress in 
parallel with the progression of the disease. Still, both cognitive deficits and 
neuropsychiatric symptoms affect the person’s ability to manage the activities of everyday 
life and cause an increased need of caregiving. In future work it would be valuable to 
examine in more detail whether some specific cognitive and neuropsyciatric domains are 
related to each other or to activities of daily living.  
 
6.1.6 Association of age, gender, and education with the progression of Alzheimer’s 
disease  
The association of the number of years of formal education with cognition has been widely 
noted previously (e.g., Karrasch et al., 2003), and in this study, too, cognition was 
associated with education. It was also noted that persons with very mild AD at baseline 
(CDR 0.5) were more highly educated than persons with mild AD. Gender was found to 
affect functional ability, with women receiving higher scores in the ADCS-ADL, which 
probably reflects the tradition of this particular generation to share housework, and this 
needs to be taken into account in the interpretation of the measures of ADL.  
 In a more detailed analysis of the CERAD-NB subtests carried out in Study III, it was 
noticed that education did not correlate with verbal fluency and the clock-drawing test, 
which both are measures of executive functions. Fluency did not correlate with education in 
Welsh et al.’s study (1994), either. However, in contrast to the findings obtained in the 
present study, a previous review suggests a link between education and the clock-drawing 
test (Pinto et al., 2009). In the past, educational opportunities were limited in Finland; 
therefore the educational level of members of the oldest age group is typically low, so that 
educational background is not necessarily a good indicator of cognitive capacity in this 
study. In Finnish normative data, both verbal fluency and the clock-drawing task correlated 
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with education (Karracsh et al., 2003). The influence of education in normal aging may be 
different from that in AD. Interestingly, educational level did not predict the progression of 
AD in this study as it has done in the many other studies (Sona et al., 2013). 
6.1.7 Predicting the progression of symptoms in Alzheimer’s disease  
 Although the ADCS-ADL was the only measure that correlated with gender, the male 
gender was associated with a faster progression rate of AD-related symptoms in Study III, 
which was in line with most previous reports (Zhou et al., 2010; Ito et al., 2011; Rountree et 
al., 2012; Sona et al., 2013). In contrast to most previous studies, however, the findings of 
this study suggested that age was not a significant predictor of the progression of AD 
symptoms (Sona et al., 2013). This discrepancy may be explained by the fact that most of 
the participants in this study were old at the onset of the disease (mean age 75.2 years).  
 In Study III, a new short version of the CERAD-NB was drawn up in order to follow up 
the progression of AD symptoms. It comprised the MMSE and tests of verbal fluency, 
constructional praxis, and clock-drawing, plus covariates (age, gender, and education). In 
addition to these subtests, naming ability was found to be a significant predictor in a 
univariate analysis. Previously, too, visuoconstructive and visuospatial skills, verbal 
fluency, and the executive function (Sarazin et al., 2005; Cosentino et al., 2006; Atchinson et 
al., 2007; Zhou et al., 2010; Musicco et al., 2010), and also global cognition (Sarazin et al., 
2005; Atchinson et al., 2004; Buccione et al., 2007) have been found to predict the 
progression rate of AD symptoms. Although the short version of the CERAD-NB explained 
the progression of AD symptoms better than the MMSE or the CERAD-NB did, its 
predictive accuracy was moderate (less than 40 %). Therefore, to predict the progression of 
AD symptoms soon after diagnosis, information about cognitive performance should be 
supplemented with information about different AD symptoms and comorbidities.  
6.2 THE EFFECT OF A PSYCHOSOCIAL INTERVENTION PROGRAMME ON 
ALZHEIMER’S DISEASE  
6.2.1 Intervention to delay institutionalisation 
Previous results of interventions to delay nursing-home placement have been 
contradictory. The meta-analyses and reviews conducted on various interventions and 
outcome measures suggest that specific interventions are effective on specific targets and 
that only multicomponent interventions have had an effect on institutionalisation. 
However, it is to be noted that meta-analyses such as Pinquart & Sörensen (2006), Olarazan 
et al. (2010), and Vugt et al. (2013) have evaluated only a limited number of studies. Study 
IV brought out no effect of early psychosocial rehabilitation on delaying nursing-home 
placement. The result concurs with those of recent studies by Brodaty et al. (2009) and 
Phung et al. (2013), in which no long-term effects of psychosocial intervention on nursing-
home placement or on other outcome measures were found. The intervention procedures, 
the follow-up times, and the participant selection in Phung et al. (2013) were similar to 
those in this study. Thus the inconsistent results obtained in other studies may be a 
consequence of different participant selection and different intervention procedures. Also, 
the decade in which the studies were conducted is probably of importance, for diagnostic 
procedures, treatment and care, and knowledge and attitudes have changed since the days 
of the older studies mentioned. Pinquart & Sörensen (2006) point out that some 
interventions may prepare the caregivers for the institutionalisation of the person with AD. 
In this study it was also noticed that the persons with AD lived at home with a family 
caregiver rather a long time. Indeed, one might ask whether it is a realistic idea at all to 
prolong the period of home care by means of intervention. Many authors emphasise that an 
intervention or a follow-up intended to assess the support needed should last long enough, 
be continuous, and be individually tailored. On the basis of previous studies and reviews, 
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the results of this study, and the findings of Välimäki et al. (2014), one may propose a 
combination of regular follow-up and individually tailored support, which takes account of 
the needs of the person with AD and the family caregiver.  
 
6.2.2 The effect of intervention on Alzheimer’s disease-related symptoms 
In Study IV, no effect of the psychosocial intervention on the progression of AD-related 
symptoms was found, which was in line with recent studies by Phung et al. (2013) and 
Brodaty et al., (2009). There is evidence that intervention can have an effect on 
neuropsychiatric symptoms (Spira et al., 2006), cognition (Spector et al., 2012), and ADL 
(Olazaran et al., 2010), but in these studies the interventions focused specifically on these 
particular outcomes. Even though the intervention group and the control group were equal 
at the baseline visit, members of the intervention group appeared in Study IV to have a 
faster progression of AD symptoms on average than those of the control group. The 
caregivers of the intervention group rated the activities of daily living and the severity of 
AD of their family members as worse than those of the control group. Possibly, the 
caregivers who received more information became more sensitive to AD-related symptoms. 
Then again, the same difference in the progression of AD-related symptoms was also noted 
in the objective measures (the MMSE and the CERAD-NB). In spite of these negative 
intervention effects, it was noticed that the patient-caregiver dyads in the intervention 
group dropped out of the study less frequently. It is a moot point, though, whether this was 
due to good experiences acquired from the intervention. In Phung et al.’s study (2013), too, 
the participants felt that they had benefited from the intervention even though no 
quantitative effects were found.  
6.3 THE CERAD NEUROPSYCHOLOGICAL BATTERY AS A FOLLOW-UP 
TOOL 
In the present study, the CERAD-NB total score was used as a follow-up measure of global 
cognitive deterioration in persons with very mild or mild AD. Originally, the CERAD-NB 
(Welsh et al., 1994) was developed to distinguish AD-related cognitive disturbances from 
changes in cognitive performance occurring in normal aging. In Finland, as in some other 
countries, the CERAD-NB has been established as a screening tool to detect cognitive 
difficulties earlier than can be done with the MMSE, and it has been used widely as a 
screening method in primary health care (Hänninen et al., 1999; Sotaniemi et al., 2012). The 
use of the total score, developed later (Chandler et al., 2005), has simplified the use of the 
CERAD-NB, especially in research settings, relative to the use of the individual subtests, 
but only a few studies (Rossetti et al., 2010; Seo et al. 2010) have analysed the usability of 
the CERAD-NB total score in follow-up studies of AD. However, especially in clinical 
practice the whole CERAD-NB total score is time-consuming and may distress persons with 
AD. There was therefore a need to develop a short version of the CERAD-NB for use 
alongside the commonly used but also criticised (Atchinson et al., 2004; Clark et al., 1999; 
Galasko et al., 2000) MMSE test. 
  
6.3.1 The use of the CERAD Neuropsychological Battery total score 
Both at baseline and during the follow-up, the CERAD-NB total score correlated strongly 
with other cognitive and global measures but not with the measure of neuropsychiatric 
symptoms; this was as expected. The CERAD-NB total score was more sensitive than the 
MMSE in distinguishing the CDR stages, and it did not show floor or ceiling effects. At 
every follow-up visit in Study II, the CERAD-NB indicated that the differences in cognition 
between the two groups with different severity of dementia at baseline (CDR 0.5 and CDR 
1) remained but that the rates of decline were identical. These results are in line with 
previously reported ones (Rossetti et al., 2010; Seo et al., 2010) and support the use of the 
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CERAD-NB total score not only as a screening tool but also as a suitable and sensitive 
follow-up tool for measuring global cognition during the progression of AD. 
  
6.3.2 The use of the subtests of the CERAD Neuropsychological Battery  
Generally, performance in all the subtests declined during the three years in Study III. An 
explorative short version of the CERAD-NB was drawn up, including the MMSE, verbal 
fluency, constructional praxis, and the clock-drawing test, and this subtest combination was 
found to get support from previous cross-sectional studies (Barth et al., 2005; Bertolucci et 
al., 2001; Welsh et al., 1992; Pinto et al., 1999). These subtests measure executive functions 
and visuospatial skills, and in a recent meta-analysis an association was found between 
executive functions and activities of daily living in dementia (Martyr & Clare, 2012), and 
visuospatial skills have also been found to be associated with the progression of functional 
decline (Atchinson et al., 2007). These findings support the interpretation that the test 
results from the new short version of the CERAD-NB may reflect the person’s ability to 
carry out daily functions. Although memory problems are the first signs of the disease, test 
results derived from other cognitive domains may be more useful for monitoring the 
progress of the disease, as pointed out by Welsh et al. (1992). The test of verbal fluency and 
the clock-drawing test were the only subtests that were not associated with education, 
which makes the interpretation of their results easier.  
  
6.3.3 The new short version of the CERAD Neuropsychological Battery 
In Study III, a new short version of the CERAD-NB was developed and found to be more 
comprehensive than the MMSE alone while yet relatively brief and easy to administer. It 
may facilitate the following up of the progression of AD by providing a tool for assessing 
the progression of cognitive deficits. Thus it may be applied to the planning of treatment 
and care, for instance. However, this explorative model must be tested with other samples 
to establish its usability. It should also be kept in mind that these results concerning 
cognitive assessment do not reduce the need of multifaceted evaluation, including 
information about the functional ability, psychological and behavioural symptoms, and the 
life situation of the person with AD, as well as the family caregiver’s situation, in the 
monitoring of the progression of AD in clinical and research settings.  
6.4 STRENGTS AND LIMITATIONS OF THE STUDY 
 The ALSOVA Study, a prospective, randomised, and controlled trial of early 
psychosocial intervention for persons with very mild or mild AD and their caregivers with 
a relatively long follow-up, was one of the largest published. The participants were 
recruited soon after their diagnosis and were treated within the regular health care system, 
including treatment with AD-targeted medication. The study population was 
homogeneous, representing persons with AD living at home with their caregivers and 
normal heath-care support. Persons with other neurodegenerative diseases or more severe 
AD at baseline, as well as persons with comorbidities that could affect cognition, were 
excluded.  
 This study set out to add to our knowledge of the progression of cognitive deficits and 
clinical symptoms in persons with very mild or mild Alzheimer’s disease. Several different 
measures were used simultaneously, including a more extensive evaluation of cognition 
than is often used, in a fairly large study population with a longitudinal design. The 
measures used were validated and well known, and they have been used with other 
populations and cultures and in clinical practice.  
 There are certain limitations in this study. The course of AD is usually longer than three 
years (American Psychiatric Association, 2013), so that most participants still had mild AD 
at the end of the study. A longer follow-up would provide more information about the 
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severe phase and the last years of the course of AD, but then, matters such as the drop-out 
rate and the ability of persons with moderate and severe AD to perform cognitive tests 
might become problems. All the participants and their caregivers participated in this 
longitudinal intervention study voluntarily, which may have produced a selection bias. The 
participants were required to have a family caregiver and not to have severe problems with 
vision or hearing or other conditions that could have affected their cognition. Because of 
that and the homogeneity of the population in terms of all having a recently diagnosed very 
mild or mild AD, the results may not be generalisable to persons with more advanced AD, 
persons with comorbid conditions, or persons living alone or in nursing homes. The 
educational level of older persons in Finland is often lower than that in other Western 
countries, which needs to be considered in the interpretation of education-related results. 
The participants of the intervention group dropped out more seldom than those of the 
control group. This may have caused a higher proportion of persons with more severe 
symptoms in the intervention group at the end of the study, which may have affected the 
group comparisons in Study IV.   
 Before the data for Study III was analysed, all CDR stages were re-calculated, which 
resulted in changing the classification of some borderline cases. In Study III, the CDR 0.5 
group was more highly educated than the CDR 1 group, which had not been the case in 
Study I. It is possible that some highly educated persons were classified to have mild AD 
because of a notable decline in their memory from the baseline level even though their 
functional ability was still fairly good because of a cognitive reserve. However, this did not 
affect the continuous CDR-sb variable.  
 It should also be acknowledged that in the measuring of variables that were not directly 
observable, the measures themselves posed some possible limitations. The group 
differences, or lack of them, obtained in the CERAD-NB subtests may reflect not only the 
nature and progression of AD but also the properties of the measures. The decline of scores 
found in some subtests came close to showing a floor effect during the three-year follow-
up, which was in line with the results reported by Welsh et al. (1991). In contrast, the 
decline in some other subtests was slow, especially in the CDR 0.5 group.   
 During the three-year follow-up, almost a half of the participants dropped out, as might 
have been expected of this age group (e.g., Phung et al., 2013), which could have led to a 
bias in the results. Even though the drop-out rate was so high, the GEE modelling method 
was used in Study III. The advantage of this method is its capability to use all available 
longitudinal data. Other statistical methods often require complete data on every subject, or 
else the subject must be excluded from the analysis.  
 In the ALSOVA Study, the persons with AD were required to have a family caregiver 
who had regular contacts with the person, and the end-point of the study was 
institutionalisation, which may limit the generalisability of the results. On the other hand, 
these specifications enabled us to collect interview data on the subjects’ actual functional 
ability at home. Furthermore, one aim of the study was to evaluate the progression of AD-
related symptoms in persons with mild AD who lived at home by means of help from their 
family caregivers. Thus the results may not be generalisable to persons living alone or in 
nursing homes. 
6.5 SUGGESTIONS FOR FUTURE RESEARCH 
 The emphasis of research in recent years has been on early detection of AD. Less 
attention has been paid to assessing the progression of the disease, which is, after all, 
essential for the planning of functional treatment and care. The measurements used are 
rather variable, and the follow-up periods are often quite short. In this study, a new short 
version of the CERAD-NB was put forward, but its usability needs to be tested on another 
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population. So does its accuracy of assessment and prediction at the level of the individual 
patient.  
 The associations of global cognition and neuropsychiatric symptoms with the activities 
of daily living raise the interesting question of whether these associations can be accounted 
for by some specific domains. A further interest is whether there are correlations to be 
found between some specific cognitive and neuropsychiatric domains.  
 The participants of this study had been advised to use AD-targeted medication. It would 
also be of interest and value to investigate how the use of other medications, especially 
psychopharmacon, relates with cognition.  
 For modelling and predicting the progression of AD-related symptoms after diagnosis, it 
would be interesting to improve the existing models by applying multiple domains. For 
example, information on cognition, the activities of daily living, neuropsychiatric 
symptoms, comorbidities, use of medication, the social and health-care resources available, 
and caregiver-related factors could be analysed all at the same time.  
 On the basis of the results of this study, it may be concluded that the multifaceted 
psychosocial intervention did not delay the nursing-home placement or affect the AD-
related symptoms of the subjects. Even so, the fact that the drop-out rate was lower in the 
intervention group, the experiences gained from clinical practice, and the qualitative 
analyses carried out on the ALSOVA data (Välimäki 2012) suggest that help and support is 
needed for persons with AD and their families. It is necessary to develop and evaluate an 
individually tailored support programme, which takes into account the needs of both the 
person with AD and the caregiver.  Besides, the utililisation rates of social and health-care 
services could be analysed so as to assess the cost-effectiveness of the intervention 
provided.  
6.6 IMPLICATIONS FOR HEALTH CARE 
 In clinical practice, as in research, a great deal of attention has been paid to early 
detection of AD. But that is not enough. After the diagnosis, the person must not be left 
alone but needs to be followed up regularly. Appropriate support, treatment, and care 
should be provided for persons with AD and their families alike. This study provides new 
insights into the progression of symptoms in AD during three years after the diagnosis in 
persons treated in the Finnish health-care system. These results may help clinicians to 
inform persons with AD and their caregivers on the progression of the disease during the 
first few years after the diagnosis. The results may also enable clinicians and decision-
makers to plan better treatment and care and evaluate their effectiveness from the point of 
view of both the individual and the society. Especially when these results are combined 
with other results from the ALSOVA Study, such as those concerning the use of medication, 
quality-of-life aspects, neuropsychiatric symptoms, the use of resources, and caregiver-
related factors, a versatile and unique model of the progression of AD can be provided for 
research, clinical, and societal use.   
 In this study, persons with very mild AD at baseline showed a slower decline of daily 
functions and fewer neuropsychiatric symptoms than persons with mild AD at baseline 
did. These findings emphasise the significance of early diagnosis. They also point at the 
importance of using sensitive methods to measure cognition and assess the 
neuropsychiatric symptoms and the activities of daily living both at the diagnostic visit and 
during the follow-up. The new short version of the CERAD-NB (including the MMSE) 
could improve the follow-up assessments of the progression of AD-related symptoms in 
clinical settings as well.  
 The results of this study do not support the recommendation to automatically offer early 
intensive psychosocial intervention to all persons with very mild or mild AD and their 
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caregivers. The life situation and needs of both the person with AD and the caregiver need 
to be evaluated and individually tailored help and support be offered.  
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7 Conclusions 
1. Cognitive performance, as assessed with the CERAD-NB total score and the MMSE, was 
associated with the severity of dementia and the activities of daily living in persons with 
very mild or mild AD. It did not correlate, however, with neuropsychiatric symptoms. Both 
cognitive deficits and NPS were associated with the person’s ability to manage everyday 
life activities (Study I). 
2. During the three-year follow-up, progressive deterioration was observed in cognitive 
functions and the activities of daily living, and increases were noted in neuropsychiatric 
symptoms. The decline of ADL functions was slower in persons with very mild AD at 
baseline. The CERAD-NB total score correlated with other cognitive and functional 
measures, lacked ceiling or floor effects, and outperformed the MMSE in distinguishing the 
severity stages of dementia; it was thus considered to be a suitable tool for longitudinal AD 
trials (Study II). 
3. The combination of the MMSE and the CERAD-NB subtests of verbal fluency, 
constructional praxis, and clock-drawing had the highest correlation with the severity of 
dementia during the three-year follow-up. The baseline values of this shortened version of 
the CERAD-NB, with demographical characteristics, accounted for approximately 40 % of 
the progression of the disease (Study III). 
4. The study did not show any long-term effect of early psychosocial intervention on 
nursing-home placement, the progression of AD-related symptoms, behavioural 
symptoms, or the quality of life in persons with very mild or mild AD (Study IV). 
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In recent years, the emphasis in re-
search and clinical practice concern-
ing Alzheimer’s disease (AD) has 
been on early detection of the disease. 
Besides that, ways of measuring the 
progression of AD-related symptoms 
and providing support after the diag-
nosis are also needed. In this study, 
cognition, activities of daily living, 
neuropsychiatric symptoms, and the 
severity of the disease in persons with 
very mild or mild AD at baseline were 
followed up for three years, and the 
usability of the CERAD Neuropsycho-
logical Battery as a follow-up method 
was evaluated. Furthermore, the study 
analysed the effects of early psycho-
social intervention on institutionalisa-
tion and AD-related symptoms.
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